Patients must have histologically or cytologically confirmed alveolar soft part sarcoma that is not curable by surgery; diagnosis of malignancy must be confirmed by the department of pathology at the institution where the patient is enrolled prior to patient enrollmentXx_NEWLINE_xXHistologically- or cytologically-confirmed CRC that is metastaticXx_NEWLINE_xXHistologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangementXx_NEWLINE_xXMust have histologically confirmed advanced CRC that is metastatic.Xx_NEWLINE_xXSubjects must have histologically proven GBM or AA and:Xx_NEWLINE_xXHistologically confirmed oligodendroglioma or mixed gliomaXx_NEWLINE_xXHistologically or cytologically confirmed cholangiocarcinoma.Xx_NEWLINE_xXHistologically or cytologically confirmed small cell lung cancerXx_NEWLINE_xXPatients must have histologically confirmed bone or soft tissue sarcoma by central pathology review\r\n* Patients must have histologically confirmed liposarcoma (LPS) (only dedifferentiated and pleomorphic; well differentiated not eligible), undifferentiated pleomorphic sarcoma (UPS)/malignant fibrous histiocytoma (MFH), or gastrointestinal stromal tumor (GIST)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed papillary histology renal cell carcinoma which is metastatic or locally advanced disease not amenable to surgical resection; (NOTE: a designation of type I or type II should be made by the local pathologist if possible); mixed histologies containing type I or type II will be allowed provided that they contain >= 50% of the papillary componentXx_NEWLINE_xXPatients must have pathologically/histologically confirmed tumor of non-small cell histologyXx_NEWLINE_xXPatients must have unresectable or metastatic, histologically confirmed low or intermediate grade (Klimstra Criteria) pancreatic neuroendocrine tumor (PNET) with radiological evidence of disease progression since last treatmentXx_NEWLINE_xXPatients must have a biopsy with histologically confirmed diagnosis of recurrent endometrial cancer confined to the pelvis and/or vagina and no evidence of extrapelvic diseaseXx_NEWLINE_xXPatients must have histologically or cytologically diagnosed advanced anaplastic thyroid cancer (ATC)Xx_NEWLINE_xXCOHORT B: Patients must have histologically or cytologically confirmed primary desmoplastic melanoma that is unresectable; patients in Cohort B must have measurable disease per RECIST 1.1Xx_NEWLINE_xXPatients must have pathologically (histologically or cytologically) proven diagnosis of MCC by local pathology reviewXx_NEWLINE_xXHistologically confirmed diagnosis of WHO grade II meningioma confirmed by central pathology review prior to step 2 registrationXx_NEWLINE_xXHistologically confirmed, new diagnosis of PTCLXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of limited or extensive stage SCLC which failed one prior platinum-containing regimen and with a chemotherapy-free interval (CTFI, time from the last dose of first-line chemotherapy to the occurrence of progressive disease) ? 30 days. Small-cell carcinoma of unknown primary site with or without neuroendocrine features confirmed in histology test(s) performed on metastatic lesion(s) are eligible, if Ki-67/MIB-1 is expressed in >50% of tumor cells.Xx_NEWLINE_xXPhase 1b: Histologically and/or cytologically confirmed metastatic selected solid tumor types that have progressed after treatment with approved therapies or for which there are no standard effective therapies available. If nivolumab or pembrolizumab is an approved therapy for the participant's tumor type, but the participant has not been treated with it, the Investigator may enroll the participant in this study. Phase 2: Histologically and/or cytologically confirmed metastatic selected solid tumor types with 0-2 prior lines of systemic therapy (unless discussed with the sponsor) For the non-small cell lung cancer (NSCLC) and melanoma cohorts, participants must have progressed on or after prior treatment with one anti-PD-1, anti-PD-L1, or anti-PDL2 agent Selected tumor types of both phases: NSCLC, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma (excluding uveal melanoma)Xx_NEWLINE_xXPatient has one of the following histologically or cytologically confirmed advanced malignancies: acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), glioblastoma multiforme (GBM), melanoma, non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, sarcoma, renal cell carcinoma (RCC)Xx_NEWLINE_xXParticipant must have histologically or cytologically confirmed small cell lung cancer and may not be a candidate for potentially curative therapyXx_NEWLINE_xXSubject has histologically confirmed diagnosis of GBM.Xx_NEWLINE_xXSubject with histologically or cytologically confirmed extensive-stage disease SCLC which is newly diagnosed and chemotherapy naiveXx_NEWLINE_xXPhase 1 ONLY: histologically or cytologically confirmed advanced/metastatic solid tumors for which carboplatin/etoposide treatment is considered appropriate.Xx_NEWLINE_xXPart A and A2: Participants with one histologically or cytologically confirmed malignant advanced solid tumor, for which no standard therapy is available which may convey clinical benefitXx_NEWLINE_xXParticipants must have histologically confirmed melanoma that is metastatic or unresectableXx_NEWLINE_xXPathologically confirmed relapsed/ refractory DLBCLXx_NEWLINE_xXHistologically or cytologically confirmed prostate cancerXx_NEWLINE_xXHistologically or cytologically proven diagnosis of prostate cancer, sqNSCLC, TNBC, or known PTEN-deficient solid malignancy, and is refractory to standard therapies.Xx_NEWLINE_xXEarly or confirmed evidence of progressive disease.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed non-rhabdomyosarcoma of soft tissue or bone at any siteXx_NEWLINE_xXHistologically or cytologically proven diagnosis of advanced stage angiosarcoma that is not amenable to treatment with curative intent; specify site of origin as cutaneous vs. non-cutaneousXx_NEWLINE_xXHistologically confirmed diagnosis of urothelial carcinoma of the bladder. Variant histology is acceptable if there is a predominant urothelial component.Xx_NEWLINE_xXHistologically or cytologically confirmed, resectable Stage II, IIIA, or Select IIIB (T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on the 8th edition of the AJCC/UICC staging systemXx_NEWLINE_xXPatients must have confirmed progression during or after treatment with either nivolumab or pembrolizumab. Confirmed progression is defined as:Xx_NEWLINE_xXHistologically confirmed advanced malignant melanoma, regardless of subtype (for screening and treatment phases)Xx_NEWLINE_xXHistologically confirmed metastatic colorectal cancer, not amenable to curative resectionXx_NEWLINE_xXHave histologically or cytologically confirmed SCLC that meets:Xx_NEWLINE_xXHave documented histologically or cytologically confirmed advanced NSCLC with no small cell histology or neuroendocrine histologyXx_NEWLINE_xXMust have a confirmed diagnosis of active MMXx_NEWLINE_xXIn dose expansion (part 2), patients must have histologically or cytologically confirmed unresectable or metastatic melanoma, renal cell carcinoma, ovarian cancer, or colorectal cancerXx_NEWLINE_xXParticipants with histologically confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapyXx_NEWLINE_xXHistologically confirmed or cytologically confirmed diagnosis of stage IV NSCLCXx_NEWLINE_xXPhase 1: Subjects must have a histologically or cytologically confirmed diagnosis of metastatic (AJCC stage IV) NSCLC that carries an ALK rearrangement with CNS metastases, as determined by FISH, RT-PCR, immunohistochemistry (IHC), or NGS via a CLIA-certified LDTXx_NEWLINE_xXPhase 2 Cohort C (thyroid cancer): Subjects must have a histologically or cytologically confirmed diagnosis of metastatic thyroid cancer (stage IV) that carries either a RET rearrangement or activating RET mutation, as determined by FISH, RT-PCR, or NGS via a CLIA-certified LDTXx_NEWLINE_xXPatients with histologically confirmed advanced solid tumors (regimen A) or breast or pancreas (regimen B)Xx_NEWLINE_xXHistologically confirmed diagnosis of advanced unresectable or metastatic STS, not amenable to curative treatment and after available standard therapies have failed to provide clinical benefit. Note: Participants with a diagnosis of Grade 1 liposarcoma (atypical lipomatous neoplasms) are eligible if there is histological or radiographic evidence of evolution to more aggressive disease.Xx_NEWLINE_xXHave histologically or cytologically confirmed Kaposi's sarcoma or gastrointestinal stromal tumor (GIST).Xx_NEWLINE_xXHistologically or cytologically confirmed immunotherapy naïve, metastatic or locally advanced non-small cell lung cancer not amenable to curative treatment. Subjects may be treatment naive or could have received one prior platinum based chemotherapy for non-small cell lung cancer and subjects with a documented activating mutation (e.g., EGFR, ALK, ROS) must also have received the appropriate therapy and progressedXx_NEWLINE_xXHave locally advanced (on TNM staging: T4b and any N, or any T and N2-3) or metastatic transitional cell carcinoma of the urothelium, including of the urinary bladder, urethra, ureter, and/or renal pelvis. The diagnosis must be histologically or cytologically confirmed.Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumor (including non-Hodgkin Lymphoma) (Stage IV, AJCC v.7) that harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by protocol specified tests.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed invasive breast cancer, with stage IV disease; patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluationXx_NEWLINE_xXHistologically confirmed presence of BCG-unresponsive CIS (with or without Ta or T1 disease) or histologically confirmed presence of BCG-unresponsive high-grade Ta or T1 disease.Xx_NEWLINE_xXConfirmed diagnosis of hepatocellular carcinoma (HCC)Xx_NEWLINE_xXPatients must have histologically confirmed MCM or ALM that is metastatic or unresectableXx_NEWLINE_xXHistologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXHistologically or cytologically confirmed Stage IIIb or IV non-small cell lung cancer HER2 IHC 2+ or 3+ by local laboratory assessment.Xx_NEWLINE_xXHistologically or cytologically confirmed Stage IIIb or IV breast cancer with cutaneous metastases.Xx_NEWLINE_xXHistologically confirmed pleural malignant mesothelioma not eligible for curative surgeryXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed disease from any solid tumorXx_NEWLINE_xXHistologically or cytologically documented, injectable cancer lesion (limited to solid tumors and mycosis fungoides)Xx_NEWLINE_xXParticipants must have histologically or cytologically confirmed disease from any solid tumorXx_NEWLINE_xXCOHORT D: Histologically confirmed diagnosis of melanomaXx_NEWLINE_xXPatient has histologically/cytologically confirmed, non-keratinizing/undifferentiated, EBV-related nasopharyngeal carcinoma, not amenable to curative intent therapy; EBV testing may be completed per institutional standardsXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed low- to intermediate-grade neuroendocrine tumor (carcinoid tumor)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed glioblastoma or other grade IV malignant glioma (i.e. gliosarcoma, small cell glioblastoma, etc.), recurrent after prior external beam fractionated radiotherapy and temozolomide chemotherapyXx_NEWLINE_xXHave a histologically-confirmed diagnosis of MB, NB, ES, or ARMSXx_NEWLINE_xXPart A and Part B: Has histologically or cytologically-confirmed metastatic solid tumor.Xx_NEWLINE_xXPatients who have the below specified histologically or cytologically confirmed malignancies that have progressed to the advanced or metastatic stage.Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of metastatic medullary thyroid cancerXx_NEWLINE_xXParticipant must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) that is metastatic or unresectable. Participants must have either progressed after receiving prior therapy for metastatic disease, or be ineligible for, or have refused all other currently available therapeutic optionsXx_NEWLINE_xXHistologically documented metastatic cancer (solid tumors, not including hematologic malignancies)Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of melanoma.Xx_NEWLINE_xXHistologically confirmed diagnosis of hepatocellular carcinoma (mixed HCC/cholangiocarcinoma is allowed)Xx_NEWLINE_xXHistologically or cytologically confirmed SCLC (either limited or extensive disease) or LCNEC, that has relapsed from the most current treatment or was refractory to treatmentXx_NEWLINE_xXHistologically confirmed prostate cancer; small cell/neuroendocrine differentiated allowed but not required for study participationXx_NEWLINE_xXPatients must have persistent or recurrent histologically confirmed USCXx_NEWLINE_xXParticipants must have histologically confirmed glioblastoma or variants; subjects with initial diagnosis of a lower grade glioma are eligible if a subsequent biopsy is determined to be glioblastoma or variantsXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of melanomaXx_NEWLINE_xXHistologically or cytologically confirmed incurable HNSCC of the oral cavity, oropharynx, larynx, hypopharynx, and/or level 1-3 neck node with non-skin squamous cell carcinoma (SCC) and unknown primary; “incurable” is defined as metastatic disease or a local or regional recurrence in a previously irradiated site that is unresectable (or patient declines resection)Xx_NEWLINE_xXParticipants must have histologically confirmed advanced malignancy that is metastatic and/or unresectable and/or recurrent with confirmed inactivating mutations in TSC1 or TSC2 or activating MTOR mutations, identified in any Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory; all genetic findings must be reviewed by the study principal investigator (PI), Dr. David Kwiatkowski, prior to study entryXx_NEWLINE_xXHistologically confirmed triple negative breast cancer that are refractory, intolerant, or ineligible to receive approved standard therapiesXx_NEWLINE_xXPatient must have unresectable primary tumor or metastases (including tumors with an intralesional resection)\r\n* For Stratum 1, patients must have a confirmed histologic diagnosis of osteosarcoma\r\n* For Stratum 2, any histologically confirmed solid tumor diagnosis is eligibleXx_NEWLINE_xXHistologically or cytologically confirmed advanced (stage IIIB or IV) NSCLCXx_NEWLINE_xXPatients must have histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXHistologically or cytologically confirmed advanced solid tumors including:Xx_NEWLINE_xXPatients must have histologically confirmed solid tumor that is metastatic or unresectable, and there is no available therapy likely to convey clinical benefit.Xx_NEWLINE_xXHistologically confirmed metastatic or recurrent Type II EC (serous, clear cell, carcinosarcoma, adenosquamous and mixed histologies).Xx_NEWLINE_xXParticipants must have histologically or cytologically confirmed stage IV invasive breast cancer. Participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluationXx_NEWLINE_xXHave previously untreated, histologically confirmed NSCLC and histologically confirmed Stage IIB or IIIA NSCLC.Xx_NEWLINE_xXParticipants must have histologically or cytologically confirmed stage IV uveal melanomaXx_NEWLINE_xXHas a histologically confirmed diagnosis of unresectable stage III or metastatic melanoma not amenable to local therapyXx_NEWLINE_xXHave histologically or cytologically confirmed locally advanced or metastatic transitional cell carcinoma of the urothelium (renal pelvis, ureter, urinary bladder or urethra)Xx_NEWLINE_xXEpithelial Endometrial Cancer: histologically confirmed diagnosis (by either primary surgical specimen or biopsy for recurrence) of recurrent previously treated EEC.Xx_NEWLINE_xXHave histologically confirmed GBMXx_NEWLINE_xXHas a histologically- or cytologically-confirmed advanced/metastatic solid tumor by pathology report and have received, or been intolerant to, or been ineligible for all treatment known to confer clinical benefit. Participants with solid tumors of any type are eligible for enrollment.Xx_NEWLINE_xXParticipant must have histologically or cytologically confirmed advanced malignancies, except all forms of leukemia and lymphoma, for which standard curative or palliative measures do not exist, are no longer effective, or are not acceptable to the participantXx_NEWLINE_xXHistologically or cytologically confirmed limited or extensive disease stage of SCLC. The disease should be progressing during or relapsing after the previous treatment.Xx_NEWLINE_xXHistologically confirmed diagnosis of advanced, unresectable, or metastatic soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy excluding: chondrosarcoma, neuroblastoma, osteosarcoma, embryonal rhabdomyosarcoma, or Kaposi sarcoma.Xx_NEWLINE_xXSubject must have histologically or cytologically confirmed locoregionally recurrent squamous cell carcinoma of the head and neck (including any primary site, such as oral cavity, oropharynx, larynx or hypopharynx, and nasopharynx carcinoma)Xx_NEWLINE_xXPatient must have histologically or cytologically confirmed metastatic or recurrent NSCLC which is progressing.Xx_NEWLINE_xXHistologically confirmed HER2-negative localized breast cancer by core biopsy.Xx_NEWLINE_xXPatients must have cytologically or histologically confirmed relapsed or refractory extensive-disease small-cell lung cancer (ES-SCLC) or non-progressing ES-SCLC after first line chemotherapy, or advanced or inoperable grade I-II pulmonary NETsXx_NEWLINE_xXHistologically or cytologically confirmed advanced TNBC that is relapsed, refractory, or progressive and not eligible for another standard therapy that would confer clinical benefit to the subject.Xx_NEWLINE_xXParticipants must have a histologically or cytologically confirmed advanced solid tumor of a non-breast origin, for which standard therapy proven to provide clinical benefit does not exist or is no longer effectiveXx_NEWLINE_xXHas a histologically or cytologically confirmed diagnosis of Stage IV metastatic NSCLC (American Joint Committee on Cancer version 8)Xx_NEWLINE_xXHistologically confirmed diagnosis of GISTXx_NEWLINE_xXHistologically or cytologically confirmed, treatment-naive esophageal squamous cell carcinomaXx_NEWLINE_xXMeasurable, histologically/cytologically confirmed metastatic colorectal cancer (mCRC).Xx_NEWLINE_xXParticipant has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor (ER) positive breast cancer by local laboratory.Xx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Participants must have histologically confirmed advanced NSCLC (with a confirmed KRAS mutation via any Clinical Laboratory Improvement Act [CLIA]-certified method) for which curable treatment modalities are not an optionXx_NEWLINE_xXHistologically confirmed advanced solid tumors with no clear curative treatment options available after at least 1 prior systemic anticancer therapy.Xx_NEWLINE_xXhistologically confirmed diagnosis of metastatic CRPCXx_NEWLINE_xXPart 1: any histologically-confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of stage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neck not suited for local therapyXx_NEWLINE_xXPatients with a histologically or cytologically confirmed solid tumor malignancyXx_NEWLINE_xXHistologically confirmed squamous cell carcinoma of the target tumor(s)Xx_NEWLINE_xXParticipants must have histologically confirmed adenoid cystic carcinoma with evidence of recurrent or metastatic disease not amenable to potentially curative surgery or radiotherapyXx_NEWLINE_xXHistologically or cytologically confirmed unresectable or medically inoperable malignant pleural mesotheliomaXx_NEWLINE_xXPatients must have histologically confirmed solid tumor that is metastatic or unresectable, and there is no available therapy likely to convey clinical benefitXx_NEWLINE_xXHistologically or cytologically-confirmed advanced or metastatic non-small cell lung cancer (NSCLC) that is EGFR mutation positive; rare sensitizing mutations allowedXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of locally advanced or metastatic ALK-positive NSCLC; at least 1 extracranial measurable target lesion not previously irradiated. CNS metastases allowed if asymptomatic and not currently requiring corticosteroid treatment.Xx_NEWLINE_xXPatients of any age must have histologically or cytologically confirmed embryonal or alveolar rhabdomyosarcoma (RMS) confirmed by the Laboratory of Pathology, National Cancer Institute (NCI)Xx_NEWLINE_xXHistologically confirmed GBM (WHO grade IV).Xx_NEWLINE_xXHas a histologically- or cytologically-confirmed advanced/metastatic solid tumor or lymphoma by pathology report and who has received, or been intolerant to, all treatment known to confer clinical benefit. Solid tumors and lymphomas of any type are eligible for enrollment.Xx_NEWLINE_xXSubjects with histologically or cytologically confirmed non-small cell lung cancer (NCSLC).Xx_NEWLINE_xXHistologically confirmed, stage IV or recurrent non-small cell lung cancer with no prior systemic anticancer therapy given as primary therapy for advanced or metastatic diseaseXx_NEWLINE_xXNew diagnosis of brain metastases from a histologically or cytologically confirmed primary or metastatic NSCLC tumor within 5 years of registration on the study. If the original histological proof of malignancy is greater than 5 years, then pathological confirmation is required (i.e.: from extra-cranial or intracranial disease).Xx_NEWLINE_xXHistologically confirmed muscle-invasive UC (also termed transitional cell carcinoma) of the bladder or upper urinary tract (i.e., renal pelvis or ureters)Xx_NEWLINE_xXHistologically documented metastatic cancer (solid tumors, not including hematologic malignancies)Xx_NEWLINE_xXPart F only: Patients with documented HTLV-1 infection and histologically or cytologically proven ATLL of any stage, and who are intolerant to, or have disease that is relapsed/refractory after, at least one prior therapyXx_NEWLINE_xXHistologically or cytologically proven diagnosis of non-small cell lung cancerXx_NEWLINE_xXMust have histologically or cytologically confirmed advanced pancreatic ductal adenocarcinoma (PDAC) that is metastatic. The definitive diagnosis of metastatic PDAC will be made by integrating the histopathological data within the context of the clinical and radiographic data. Patients with islet cell neoplasms are excluded.Xx_NEWLINE_xXHistologically or cytologically-documented, advanced solid tumor of one of the following types:Xx_NEWLINE_xXHistologically or cytologically confirmed metastatic UMXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed invasive breast cancerXx_NEWLINE_xXHistologically confirmed lymphoma (WHO classification), or confirmed MM (IMWG), that is relapsed and/or refractory.Xx_NEWLINE_xXSubject has histologically confirmed diagnosis of any one of the following cancers: (A) urothelial cancer (transitional cell cancer of the bladder, ureter or renal pelvis), (B) melanoma, or (C) squamous cell carcinoma of the head and neck.Xx_NEWLINE_xXPatients must have cytologically or histologically confirmed advanced NSCLC; patients with mixed histology containing a small cell lung cancer component are not eligibleXx_NEWLINE_xXFor enrollment into the MET cohort: participants must have a histologically or cytologically confirmed advanced non-small cell lung cancer (NSCLC) and must have received at least one prior line of therapy in the metastatic settingXx_NEWLINE_xXFor enrollment into the NTRK cohort: participants must have a histologically or cytologically confirmed advanced solid tumor and must have received at least one prior line of therapy in the metastatic settingXx_NEWLINE_xXDiagnosed with histologically confirmed solid tumor located in the peripheral lungXx_NEWLINE_xXHave histologically or cytologically confirmed diagnosis of advanced solid tumor cancer (excluding lymphomas) for which there is no further standard therapy or when standard therapy is contraindicated. Patients with HGG must have shown unequivocal evidence for recurrence or progression by MRI scan or must have histologically proven tumor recurrence.Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of an advanced, malignant, solid tumor(s) with all standard treatment options having been exhausted or declined.Xx_NEWLINE_xXThe patient has confirmed relapsed or refractory MMXx_NEWLINE_xXHistologically-confirmed renal cell carcinoma (any histologic subtype) without evidence of distant metastatic diseaseXx_NEWLINE_xXHistologically or cytologically confirmed non-small cell lung cancer, advanced, recurrent, or metastaticXx_NEWLINE_xXPatients must have an immune checkpoint resistant malignancy (for example, RCC, head and neck carcinoma or MSI high cancers which have approved settings for anti-PD1 treatment), confirmed histologically or cytologically.Xx_NEWLINE_xXMust have immune checkpoint naïve histologically/cytologically confirmed advanced or metastatic CRC.Xx_NEWLINE_xXHave a pathologically confirmed diagnosis of colorectal cancer, which is metastatic or otherwise unresectableXx_NEWLINE_xXHas histologically or cytologically confirmed triple negative breast carcinoma that is either metastatic (stage IV of the TNM classification) or locally recurrent and not amenable to local curative treatment.Xx_NEWLINE_xXHistologically confirmed malignant/anaplastic meningioma, WHO grade III with any prior surgeryXx_NEWLINE_xXHistopathologically confirmed diagnosis of one of the following:Xx_NEWLINE_xXHistologically or cytologically-proven non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXPatients must have histologically confirmed unresectable NSCLC for which nivolumab is clinically appropriate. Patients must have had one line of prior therapy and have progressed or have discontinued due to toxicity.Xx_NEWLINE_xXHistologically or cytologically confirmed AML according to the WHO classificationXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of prostate cancerXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of advanced disease of any of the following tumor types:Xx_NEWLINE_xXDOSE ESCALATION COHORT: Histologically or cytologically confirmed diagnosis of advanced extracranial solid tumor for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXConfirmed diagnosis of CMMLXx_NEWLINE_xXPatients must have histologically or cytologically confirmed metastatic or recurrent RCC (any histologic subtype)Xx_NEWLINE_xXHistologically or cytologically confirmed PSCCXx_NEWLINE_xXSubjects must have histologically confirmed solid malignancy that is metastatic or unresectableXx_NEWLINE_xXPatients must have histologically or cytologically confirmed LCH, ECD or HS; confirmation of outside pathology at Brigham and Women’s Hospital (BWH) will be performed but is not mandatory prior to study enrollmentXx_NEWLINE_xXHistologically/cytologically confirmed advanced/metastatic or unresectable solid tumors, no treatment optionsXx_NEWLINE_xXRadiologically confirmed disease progressionXx_NEWLINE_xXPatients must have histologically or cytologically confirmed advanced or metastatic:Xx_NEWLINE_xXPHASE I: Histologically confirmed solid tumor malignancyXx_NEWLINE_xXHistologically confirmed diagnosis of one of the following:Xx_NEWLINE_xXHistologically or cytologically proven diagnosis of NSCLC or SCLC; in cases where the histology and cytopathology results are consistent with a carcinoma but immunohistochemistry stains are indeterminate and unable to support the lungs as the most likely site of origin, the diagnosis of NSCLC or SCLC may be established in conjunction with the radiographic and clinical pictureXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of NSCLC that carries an ALK rearrangementXx_NEWLINE_xXStratum B: Patients must have a histologically confirmed diagnosis of a non-brainstem high-grade glioma (NB-HGG) that is recurrent, progressive or refractory following therapy which included radiotherapy; spinal primary disease is eligibleXx_NEWLINE_xXStratum D: Patients must have a histologically confirmed diagnosis of ependymoma that is recurrent, progressive or refractory following therapy which included radiotherapyXx_NEWLINE_xXStratum E: Patients must have a histologically confirmed diagnosis of medulloblastoma that is recurrent, progressive or refractory following therapy which included radiotherapyXx_NEWLINE_xXPhase I: histologically confirmed grade III or IV malignant glioma\r\nPhase II: histologically confirmed grade IV malignant glioma (GBM)\r\n* Note: GBM variants and secondary GBM, and suspected secondary GBM are allowed for both phase I and phase IIXx_NEWLINE_xXHistologically or cytologically confirmed non-squamous NSCLCXx_NEWLINE_xXHistologically or cytologically confirmed stage III or IV HNSCC oral cavity, hypopharynx, oropharynx, larynx (excluding p16 or human papillomavirus [HPV]-positive oropharynx primaries and sinonasal primaries)Xx_NEWLINE_xXHistologically confirmed Rb1 positive primary recurrent, progressive, or refractory central nervous system tumors; patients with low grade gliomas are excludedXx_NEWLINE_xXHistologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.Xx_NEWLINE_xX(Part 2 only) Cohort 2: Have histologically or cytologically confirmed diagnosis of nonresectable, recurrent, or metastatic biliary tract carcinoma (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or ampullary carcinoma) and have not received prior systemic anticancer therapy for advanced or metastatic disease.Xx_NEWLINE_xX(Part 2 only) Cohort 3: Have histologically or cytologically confirmed diagnosis of metastatic or locally advanced TCC of the urinary tract (bladder, urethra, ureter, renal pelvis) (T3b-T4 N0 M0, Tany N1-N3 M0, or Tany Nany M1) and are not candidates for surgery.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed urothelial tract carcinoma; patients with urothelial carcinoma of the bladder, upper tract, or urethra are eligibleXx_NEWLINE_xXParticipants must have histologically confirmed malignant tumorXx_NEWLINE_xXHistologically confirmed CAH or grade 1 ECXx_NEWLINE_xXParticipants must have histologically confirmed glioblastoma and evidence of recurrence > 2 months since last cycle of temozolomide or other alkylating agent; patients with low-grade tumors who have progressed to glioblastoma are eligibleXx_NEWLINE_xXPatients with histologically confirmed glioblastoma or other grade IV malignant glioma (i.e. gliosarcoma, small cell glioblastoma, etc.), recurrent after prior external-beam fractionated radiotherapy and temozolomide chemotherapyXx_NEWLINE_xXPart B5 only: Participants must have histologically confirmed diagnosis of B-cell iNHL, with histological subtype; prior treatment with ?2 prior chemotherapy- or immunotherapy-based regimens for iNHLXx_NEWLINE_xXCOHORT B, GROUP 5: MESOTHELIOMA: Patients must have histologically or cytologically proven diagnosis of malignant mesothelioma; both pleural and peritoneal mesothelioma are allowedXx_NEWLINE_xXHistologically confirmed metastatic renal cell carcinoma with predominantly clear cell histologyXx_NEWLINE_xXHistologically confirmed neurotropic primary melanomaXx_NEWLINE_xXPatients must have must have histologically or cytologically confirmed SCLCXx_NEWLINE_xXPatients must have histologically or cytologically malignant mesothelioma confirmed by the National Cancer Institute (NCI) Laboratory of Pathology. Patients with pleural, peritoneal, pericardial or tunica vaginalis mesothelioma are eligibleXx_NEWLINE_xXHistologically confirmed squamous cell carcinoma of the head and neck, including the following subtypes: oral cavity, oropharynx, hypopharynx, larynx.Xx_NEWLINE_xXPatient must have a histologically confirmed diagnosis hepatocellular carcinoma; known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC will be excludedXx_NEWLINE_xXPatients must have histologically or cytologically confirmed any solid tumor (cohort 1) or prostate cancer (cohort 2); no prior treatment other than testosterone lowering therapy for mCRPC is requiredXx_NEWLINE_xXAll subjects must have history of histologically confirmed small cell lung cancer. Brain biopsy is not required unless diagnosis is judged to be in doubt by the treating physicianXx_NEWLINE_xXHistologically or cytologically confirmed hepatocellular carcinoma or biliary tract cancer.Xx_NEWLINE_xXHistologically confirmed diagnosis of cHL.Xx_NEWLINE_xXPatients who have histologically confirmed metastatic or unresectable GIST.Xx_NEWLINE_xXPatients must have histologically confirmed squamous cell carcinoma of the head and neck (unresectable and not amenable to curative intent therapy)Xx_NEWLINE_xXHistologically confirmed diagnosis of supratentorial glioblastoma.Xx_NEWLINE_xXHistologically or cytologically confirmed grade 2 or 3 soft tissue sarcoma that is unresectable or metastatic that would be standardly treated with gemcitabine or gemcitabine and docetaxel; prior surgery for primary or metastatic disease after chemotherapy following a response is allowedXx_NEWLINE_xXHistologically or cytologically confirmed metastatic or advanced inoperable diagnosis of non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXHistologically or cytologically confirmed advanced/metastatic solid tumor and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participantXx_NEWLINE_xXHistopathologically confirmed diagnosis of metastatic NSCLC.Xx_NEWLINE_xXHistologically confirmed epithelial or biphasic pleural or peritoneal mesothelioma not amenable to potentially curative surgical resection; however, patients with biphasic tumors that have a more than or equal to 50% sarcomatoid component will be excluded; the diagnosis will be confirmed by the Laboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI)Xx_NEWLINE_xXHistologically or cytologically confirmed non-small cell lung cancer, performed on a biopsy that occurred within the last 60 daysXx_NEWLINE_xXHave a histologically confirmed advanced solid tumor for which curative treatment is not availableXx_NEWLINE_xXPatients must have histologically or cytologically confirmed metastatic colorectal cancer.Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of early stage prostate cancerXx_NEWLINE_xXHistologically confirmed classical HCL by the enrolling institutionXx_NEWLINE_xXHistologically or cytologically confirmed non-small cell lung cancerXx_NEWLINE_xXPatients must have histologically confirmed melanoma that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXCOHORT 3: ENDOMETRIAL CANCER: Patients must have histologically or cytologically confirmed persistent or recurrent advanced or metastatic invasive endometrial cancer (EC) for which standard curative measures do not exist or are no longer effectiveXx_NEWLINE_xXParticipant has a prior histologically-confirmed diagnosis of a grade III or IV glioma, or has a prior histologically-confirmed diagnosis of a grade II glioma and now has radiographic progression consistent with a grade III or IV malignant glioma (MG)Xx_NEWLINE_xXSubjects must have histologically confirmed solid tumor malignancy that is metastatic or treatment refractory cancers which are not curable or do not have known palliative measures or treatments that are associated with a survival advantage (as defined by the subject or the physician investigator); enrollment of subjects with tumors that can be safely biopsied is encouragedXx_NEWLINE_xXHistologically confirmed, unresectable advanced solid malignancy with documented disease progression after at least 1 prior systemic therapyXx_NEWLINE_xXHistologically or cytologically confirmed BRAFV600 wild-type melanomaXx_NEWLINE_xXHas histologically confirmed diagnosis of RCC with clear cell component with or without sarcomatoid features.Xx_NEWLINE_xXPatients must have histologically confirmed new diagnosis of breast cancerXx_NEWLINE_xXHistologically confirmed metastatic or recurrent squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx & larynx) that is not amenable to curative therapy.Xx_NEWLINE_xXConfirmed HCC based on histopathological findings from tumor tissues. Unresectable HCC with diagnosis confirmed pathologically or with noninvasive methods.Xx_NEWLINE_xXPrior diagnosis of Langerhans cell histiocytosis (strata A and B) or LCH-related disorder (stratum C) established by standard diagnostic criteria and confirmed histologicallyXx_NEWLINE_xXHistologically confirmed prostate cancer (mixed histology is acceptable, with the exception of the small cell pure phenotype, which is be excluded)Xx_NEWLINE_xXHistologically or cytologically proven diagnosis of breast cancer with evidence of metastasis.Xx_NEWLINE_xXHistologically or cytologically confirmed ovarian epithelial cancerXx_NEWLINE_xXHistologically confirmed non-squamous NSCLC, with incurable advanced or metastatic diseaseXx_NEWLINE_xXFor patients with metastatic colorectal cancer:\r\n* Stage IV histologically-proven colorectal adenocarcinoma\r\n* Liver metastasis confirmed to be surgically resectable, with surgery evaluation and planned resection; may have minimal extrahepatic disease that is determined to be resectable\r\n* Tumor must be confirmed to be microsatellite stable (MSS); if not already reported at a Clinical Laboratory Improvement Act (CLIA)-certified laboratory, we will be able to perform this at Emory University\r\n* No prior immunotherapy\r\n* No cancer chemotherapy treatment 2 weeks prior to day 1 of treatmentXx_NEWLINE_xXHave a histologically or cytologically confirmed diagnosis of unresectable stage III or IV melanoma; patient may not have a diagnosis of uveal or mucosal melanomaXx_NEWLINE_xXHistologically or cytologically confirmed metastatic, non-squamous or squamous Non-Small Cell Lung Cancer (NSCLC)Xx_NEWLINE_xXHave a histologically confirmed diagnosis of NSCLCXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of selected advanced or metastatic solid tumors.Xx_NEWLINE_xXHave pathologically confirmed DLBCL on biopsyXx_NEWLINE_xXHistologically confirmed advanced refractory solid tumor that is measurable or evaluable per RECIST 1.1 criteria.Xx_NEWLINE_xXPatients must have histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme), established by biopsy or resection not more than 3 months prior to registrationXx_NEWLINE_xXSubjects must have histologically confirmed malignancy that is metastatic or unresectable and for which there is no available therapy likely to convey clinical benefit.Xx_NEWLINE_xXPatients must have histologically and or cytologically confirmed metastatic colorectal cancerXx_NEWLINE_xXPatients with histologically or cytologically confirmed stage IV NSCLC not amendable to curative surgery or radiationXx_NEWLINE_xXHistologically or cytologically confirmed prostate carcinoma.Xx_NEWLINE_xXHistologically or cytologically-confirmed diagnosis of metastatic KRAS wildtype colorectal cancer (CRC)Xx_NEWLINE_xXPatients must have histologically confirmed low or high grade glioma (grade II-IV)Xx_NEWLINE_xXHave histologically or cytologically confirmed diagnosis of SCCHN irrespective of PD-L1 status, which is either inoperable and recurrent, or metastaticXx_NEWLINE_xXPhase 1: Participants must be diagnosed with histologically confirmed solid tumors (excluding CNS tumors), which is relapsed or refractory, and for which there are no currently available therapies.Xx_NEWLINE_xXHistologically confirmed or radiographic evidence of recurrent/progressive high-grade glioma after treatment with bevacizumabXx_NEWLINE_xXSubjects with histologically confirmed metastatic or unresectable breast cancerXx_NEWLINE_xXHistologically or cytologically confirmed metastatic or unresectable CRC that is relapsed, refractory, or progressive following at least 2 prior systemic regimens in the metastatic setting.Xx_NEWLINE_xXHistologically confirmed advanced cancer or metastasis, which has not responded to standard therapy, producing intractable chronic pain in the target area.Xx_NEWLINE_xXHistologically proven non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXPatients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXFor all arms except Arm G, subjects must be refractory to, or intolerant of, established therapy known to provide clinical benefit for their conditions, or where subjects refuse existing therapies. For Arm G, subjects must have newly histologically or cytologically confirmed diagnosis of locally advanced cervical cancer confined to the pelvis only.Xx_NEWLINE_xXHistologically or cytologically confirmed non-small cell lung cancer, performed on a biopsy that occurred within the last 120 daysXx_NEWLINE_xXConfirmed or suspected diagnosis of stage IV or recurrent non-small cell lung cancer (NSCLC); for suspected NSCLC, diagnosis must be histologically or cytologically confirmed prior to start of nivolumab treatment; neuroendocrine cancers, or mixed neuroendocrine features in > 10% of tumor cells, are excludedXx_NEWLINE_xXPatients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary, follicular, Hurthle cell or poorly differentiated subtypes and their respective variants)Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC) (stage IV, American Joint Committee on Cancer [AJCC] v7.0) that carries an ALK rearrangement, as determined by the Food and Drug Administration (FDA)-approved fluorescence in situ hybridization (FISH) test, using Vysis ALK Break apart FISH Probe, or the Ventana immunohistochemistry (IHC) test; diagnosis using next generation sequencing (NGS) via a local diagnostic test will be accepted for enrollment but will need to be confirmed with either FISH or IHCXx_NEWLINE_xXhave a histologically confirmed diagnosis of ER+ breast cancer;Xx_NEWLINE_xXPatient has histologically confirmed locally recurrent or metastatic predominantly clear cell renal cell carcinoma.Xx_NEWLINE_xXHistologically proven mRCC with a clear cell componentXx_NEWLINE_xXHistologically confirmed advanced TET (thymoma or thymic carcinoma)Xx_NEWLINE_xXHistologically confirmed CD30-positive lymphoma with cutaneous presentationXx_NEWLINE_xXHistologically or cytologically confirmed malignant melanoma at Screeningthat is unresectable/unresected Stage IIIB, IIIC, IIID or IV. Patients with unresectable mucosal melanoma may be enrolled after consultation with the Medical Monitor.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed non-mucinous, epithelial stage 3 or 4 carcinoma of the ovary, fallopian tube or peritoneumXx_NEWLINE_xXHistologically proven diagnosis of grade 1, 2, or 3A FLXx_NEWLINE_xXHistologically or cytologically confirmed solid tumor cancerXx_NEWLINE_xXHistologically or cytologically confirmed previously untreated non-small cell lung cancer. If a diagnostic biopsy is available, a pre-treatment biopsy is not required. Patients with a suspected lung cancer are eligible, but pathology must be confirmed prior to initiating treatment on study. Neuroendocrine carcinomas are not eligible. Carcinomas with neuroendocrine differentiation are eligibleXx_NEWLINE_xXDiagnosis of histologically confirmed invasive primary rectal carcinomaXx_NEWLINE_xXParticipants must have histologically confirmed metastatic or unresectable melanomaXx_NEWLINE_xXPatients must have histologically or cytologically confirmed metastatic/recurrent adenoid cystic carcinoma (ACC) or non-adenoid cystic carcinomas (non-ACC) of major or minor salivary glandsXx_NEWLINE_xXSuspected or histologically/cytologically confirmed oropharyngeal squamous cell carcinoma (OPSCC), stage II, III, or IVA (according to the American Joint Committee on Cancer [AJCC] 7th edition), or patients with loco-regional recurrence from an OPSCC primary, if time of recurrence is at least 6 months after completion of initial curative intent treatment (surgery or radiotherapy +/- chemotherapy or cetuximab). Patients with a suspected lesion may be enrolled and a baseline biopsy will be obtained as part of the study. If squamous cell histology is not confirmed, patients will be discontinued from the studyXx_NEWLINE_xXPatients with chemo-sensitive histologically confirmed NHL will be eligible for this treatment protocol contingent on histologic sub-classificationXx_NEWLINE_xXHistologically confirmed malignancy of the bladderXx_NEWLINE_xXHistologically- or cytologically- confirmed CRCXx_NEWLINE_xXSubjects must have histologically or cytologically confirmed metastatic triple negative breast cancerXx_NEWLINE_xXHistologically confirmed renal cell carcinoma (RCC)Xx_NEWLINE_xXPatients must have pathologically confirmed HPV-positive head and neck squamous cell carcinoma of the oropharynx; confirmed HPV-positive disease of other subsites are uncommon but also eligibleXx_NEWLINE_xXPatients must have histologically confirmed metastatic or recurrent endometrial cancer; eligible histologies include but are not limited to endometrioid, serous, clear cell, carcinosarcoma, adenosquamous, and mixed histologiesXx_NEWLINE_xXMust have a histologically or cytologically confirmed, incurable malignancy, for which further standard treatment is not currently available.Xx_NEWLINE_xXSubjects must have a histologically confirmed diagnosis of small cell lung carcinomaXx_NEWLINE_xXHistologically or cytologically proven squamous cell carcinoma of the head and neck (lip, oral cavity, oropharynx, larynx, hypopharynx, non- Epstein–Barr virus [EBV] related nasopharynx, sinonasal, cutaneous), not amenable to curative intent therapyXx_NEWLINE_xXPatients must have histologically or cytologically confirmed ER and/or PR positive, HER-2/neu negative metastatic breast cancer; they can be enrolled in any line of therapy without investigational agents and should have stable disease or a partial response (which can be determined clinically) on current systemic treatment; patients must also have pathologic OR radiographic evidence of bone metastases and >= 5 CTCs; (Note: the pathology report that is used by the physician to determine diagnosis, will be used to determine patient eligibility; ER and PR status should be available at the time of registration)Xx_NEWLINE_xXHistologically or cytologically confirmed recurrent non-small cell lung cancer not amenable to curative intent therapy or stage IV NSCLCXx_NEWLINE_xXHistologically confirmed colorectal cancerXx_NEWLINE_xXHistologically confirmed FL.Xx_NEWLINE_xXCytologically or histologically confirmed advanced or metastatic HCC; if no histological diagnosis, patient must have imaging studies compatible with HCCXx_NEWLINE_xXHistologically confirmed high grade astrocytomaXx_NEWLINE_xXSubject has predominant histologically or cytologically confirmed neuroendocrine prostate cancer (mixed histology is permissible, as is positivity of serum CgA and CEA)Xx_NEWLINE_xXPatient has histologically or cytologically confirmed non-small cell lung cancer not amenable to curative intent therapy or stage IV NSCLCXx_NEWLINE_xXHistologically or cytologically confirmed TNBC based on the most recent analyzed biopsy or other pathology specimen. TNBC determination as per local institution as per standard guidelines.Xx_NEWLINE_xXHistologically confirmed cancers for which no curative therapy exists.Xx_NEWLINE_xXHistologically or cytologically confirmed hematologic malignancyXx_NEWLINE_xXPatients must have histologically or cytologically confirmed epithelial endometrial carcinoma; all histologies are accepted; patients with diagnosis of endometrial carcinosarcoma will be enrolled in the exploratory cohort (arm C) and will receive combination of cabozantinib and nivolumabXx_NEWLINE_xXHistologically or cytologically documented transitional cell carcinoma of the urothelium (squamous differentiation or mixed cell types allowed).Xx_NEWLINE_xXHistologically confirmed diagnosis of RCCXx_NEWLINE_xXSubject has histologically or cytologically confirmed diagnosis of advanced non-small cell lung cancer (stage IIIB or IV) or recurrent diseaseXx_NEWLINE_xXSubjects with histologically or cytologically confirmed extensive stage disease SCLCXx_NEWLINE_xXArm A 14-patients expansion cohort: patients with histologically or cytologically proven chemotherapy naive unresectable malignant pleural or peritoneal mesotheliomaXx_NEWLINE_xXHistologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) (oral cavity, oropharynx, hypopharynx, or larynx) not amenable to therapy with curative intent (surgery or radiation therapy with or without chemotherapy); patients who refuse radical resection are eligibleXx_NEWLINE_xXHistologically confirmed squamous cell carcinoma of any other primary anatomic location in the head and neck (e.g. paranasal cavity) and non-squamous histologies (e.g. nasopharynx or salivary gland)Xx_NEWLINE_xXPatients must have histologically documented or cytologically confirmed Hodgkin lymphoma; confirmation must include CD30 expressionXx_NEWLINE_xXPHASE IB DOSE EXPANSION: Histologically confirmed classical or lymphocyte predominant Hodgkin’s diseaseXx_NEWLINE_xXPHASE II: Histologically confirmed B-cell NHL:\r\n* Cohort 1: with only de novo DLBCL,\r\n* Cohort 2: with only FL of grade 1, 2 or 3aXx_NEWLINE_xXPatients must have histologically confirmed neuroendocrine tumor (grades 1-3) that is metastatic or unresectable, and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXPatients must have histologically documented or cytologically confirmed Hodgkin lymphoma with CD30 expressionXx_NEWLINE_xXPhase I portion of the study: Patients with histologically confirmed classical hairy cell leukemia (HCL)Xx_NEWLINE_xXHistologically or cytologically confirmed malignant secretory or non-secretory pheochromocytoma or paraganglioma that is unresectable and deemed inappropriate for alternative local regional therapeutic approachesXx_NEWLINE_xXHistologically confirmed prostate cancer of any stage undergoing RPXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the small intestine that is advanced (not amenable to surgery) or metastatic (clinical stage IV); for the purposes of this study, ampullary tumors are considered a part of the duodenum and are classified as adenocarcinomas of the small intestineXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed carcinoma; central pathology review is not required; however, pathology will be reviewed at the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns HopkinsXx_NEWLINE_xXPathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinomaXx_NEWLINE_xXPatients must have histologically confirmed diagnosis of chordoma; the pathologic confirmation may be from another metastatic siteXx_NEWLINE_xXHistologically confirmed stage 3A non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXPatients with histologically or cytologically confirmed, resectable colon cancer and other resectable cancers without distant metastases, who are candidates for surgical resection of the tumorXx_NEWLINE_xXHistologically or cytologically confirmed squamous cell carcinoma of the head and neck that is metastatic or recurrent and not treatable with curative intentXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of advanced stage gastric, gastro-esophageal, or esophageal cancers in whom ramucirumab and paclitaxel are reasonable treatmentsXx_NEWLINE_xXpatients with a histologically confirmed diagnosis of advanced, unresectable, and/or metastatic solid tumours (any type).Xx_NEWLINE_xXpatients with a histologically confirmed diagnosis of select advanced, unresectable, and/or metastatic solid tumours with specific histology/tumour types and/or specific genetic profilesXx_NEWLINE_xXPatients must have histologically or cytologically confirmed incurable non-small cell lung cancer that harbors an activating mutation in EGFR, MET, BRAF, V600E, RET, HER2, translocation in Alk, or translocation in ROS-1Xx_NEWLINE_xXPatients with histologically confirmed classical HL that is relapsed or refractory after at least one prior therapy are eligible\r\n* Patients with lymphocyte predominant Hodgkin’s are eligibleXx_NEWLINE_xXPatients must have histologically or cytologically confirmed prostate cancer (CaP); CaP can be recurrent disease after definitive therapy (radical prostatectomy or radiation therapy) for localized CaP, or metastatic CaPXx_NEWLINE_xXParticipants must have histologically confirmed small cell lung carcinoma not amenable to initial concurrent radiotherapy (extensive-stage disease)Xx_NEWLINE_xXHave histologically or cytologically confirmed diagnosis of pancreatic carcinomaXx_NEWLINE_xXDiagnosis with a histologically confirmed non-small cell lung cancer (NSCLC) or other refractory solid tumor that is metastatic or unresectable for which there is no standard curative or palliative treatment option available and where targeting EGFR may be appropriateXx_NEWLINE_xXHistologically confirmed prostate cancer (mixed histology is acceptable, with the exception of the small cell pure phenotype, which is be excludedXx_NEWLINE_xXPatients must have histologically or cytologically confirmed solid organ malignancyXx_NEWLINE_xXPatients enrolled in the expansion cohort must have histologically or cytologically confirmed squamous non-small cell lung cancer (NSCLC), breast or pancreaticobiliary tract cancerXx_NEWLINE_xXPHASE II: Patients must have histologically or cytologically confirmed, PIK3CA mutant metastatic colorectal cancer; PIK3CA status must be confirmed by tumor sequencing conducted in a Clinical Laboratory Improvement Act (CLIA) certified labXx_NEWLINE_xXA histologically or pathologically confirmed diagnosis of AML based on WHO classification with or without extramedullary disease except for central nervous system disease.Xx_NEWLINE_xXHistologically or cytologically confirmed HNSCC of the oral cavity (OC; more than 90% patients have HPV negative cancer) or oropharynx (about 60-80% of patient have HPV positive cancer)Xx_NEWLINE_xXHistologically cytologically confirmed NSCLCXx_NEWLINE_xXPatients must have histologically or cytologically confirmed cancer of prostate (CaP); CaP can be recurrent disease after definitive therapy (radical prostatectomy or radiation therapy) for localized CaP, or metastatic CaPXx_NEWLINE_xXHistologically confirmed epithelial or biphasic mesothelioma not amenable to potentially curative surgical resection; however, patients with biphasic tumors that have a >= 50% sarcomatoid component will be excluded; the diagnosis will be confirmed by the Laboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI)Xx_NEWLINE_xXSubjects must have histologically or cytologically confirmed recurrent head and neck cancerXx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of metastatic, progressive urothelial carcinoma of the bladder, urethra, ureter, or renal pelvisXx_NEWLINE_xXPatients must be diagnosed with relapse of previously histologically confirmed PFEPNXx_NEWLINE_xXPHASE II SCLC: Patients must have histologically or cytologically confirmed diagnosis of SCLC from a Clinical Laboratory Improvement Act (CLIA)-certified laboratoryXx_NEWLINE_xXUROTHELIAL CARCINOMA EXPANSION COHORT: Patients must have a histologically confirmed diagnosis of urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis from a CLIA-certified laboratory, with measurable disease by RECIST (version 1.1) including lymphadenopathy and visceral metastatic diseaseXx_NEWLINE_xXHistologically or cytologically confirmed small cell lung cancer (SCLC)Xx_NEWLINE_xXPatients with a histologically confirmed or presumed diagnosis of gynecologic malignancy for whom chemotherapy with paclitaxel and carboplatin is plannedXx_NEWLINE_xXSubjects with histologically confirmed metastatic breast cancer that is either TNBC or HR-positiveXx_NEWLINE_xXPatients must have histologically documented or cytologically confirmed Hodgkin lymphoma with CD30 expressionXx_NEWLINE_xXPatients must have histologically or cytologically confirmed progressive advanced or metastatic solid tumor of one of the following:Xx_NEWLINE_xXHistologically confirmed diagnosis of cluster of differentiation (CD)30-positive ALCL with documented ALK-positive statusXx_NEWLINE_xXPatients must have histologically confirmed diagnosis of melanoma; the pathologic confirmation may be from another metastatic site or from metastatic brain or spine lesionsXx_NEWLINE_xXHistologically or cytologically confirmed pleural malignant mesothelioma, epithelial or biphasic subtypesXx_NEWLINE_xXHistologically or cytologically confirmed malignant melanoma from skin, or mucosal melanoma (i.e. ocular melanoma subjects are not eligible)Xx_NEWLINE_xXHas a histologically or cytologically confirmed diagnosis of a solid tumor malignancy (except for any excluded malignancies listed in the Exclusion Criteria) that is not responsive to standard therapy(ies) or for which there is no approved therapy.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed small cell lung cancerXx_NEWLINE_xXHistologically confirmed soft tissue sarcoma of the extremity/trunkXx_NEWLINE_xXDiagnosis of histologically or cytologically confirmed metastatic or non-resectable synovial sarcomaXx_NEWLINE_xXHave histologically- or cytologically- confirmed unresectable or metastatic ACC that is considered incurable by local therapiesXx_NEWLINE_xXHistologically confirmed epithelioid predominantly (> 70%) subtype malignant pleural mesotheliomaXx_NEWLINE_xXHistologically confirmed CD20-positive DLBCL, any stage, bulky or nonbulky diseaseXx_NEWLINE_xXPatients must have histologically confirmed Kaposi sarcoma (KS) confirmed by the Laboratory of Pathology, National Cancer Institute (NCI)Xx_NEWLINE_xXHistologically confirmed DLBCL (WHO classification).Xx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of endometrial cancer and no clinical evidence of extra-uterine disease on preoperative evaluationXx_NEWLINE_xXHistologically confirmed diagnosis of CD20 positive iNHL with histological subtype limited to:Xx_NEWLINE_xXHistopathologically confirmed glioblastoma or gliosarcoma (WHO Grade IV) confirmed by local pathology tissue screening.Xx_NEWLINE_xXPatients with histologically confirmed KRAS positive metastatic colorectal cancerXx_NEWLINE_xXPatients must have histologically or cytologically confirmed malignant pleural mesothelioma (MPM)Xx_NEWLINE_xXHave a histologically confirmed advanced solid tumor for which curative treatment is not availableXx_NEWLINE_xXHistologically or cytologically confirmed carcinoma of the prostate (excluding neuroendocrine differentiation or squamous cell histology)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed clear cell renal cell carcinoma (RCC)Xx_NEWLINE_xXHistologically confirmed diagnosis of melanomaXx_NEWLINE_xXCAPMATINIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanomaXx_NEWLINE_xXCERITINIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanomaXx_NEWLINE_xXREGORAFENIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanomaXx_NEWLINE_xXENTRECTINIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanomaXx_NEWLINE_xXHave histologically or cytologically-confirmed head and neck squamous cell carcinoma of the oral cavity (excluding lip), oropharynx, hypopharynx, or larynx.Xx_NEWLINE_xXHistologically confirmed non-metastatic high-risk clear cell RCC (T2a-T4NanyM0 or TanyN1M0)Xx_NEWLINE_xXHistologically confirmed primary glioblastoma multiforme (GBM)Xx_NEWLINE_xXHistologically or cytologically confirmed carcinoma of the prostate (excluding neuroendocrine differentiation or squamous cell histology)Xx_NEWLINE_xXHistologically confirmed malignant extra-cranial solid tumor or desmoid fibromatosis.Xx_NEWLINE_xXHistologically or cytologically confirmed solid tumors or lymphomas that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXHistologically and radiologically confirmed advanced metastatic CCRCC in patients who have had at least one prior systemic therapy, which can include axitinibXx_NEWLINE_xXHistologically or cytologically confirmed advanced (stage IIIB or IV) non-squamous, non-small cell lung cancerXx_NEWLINE_xXNewly diagnosed, histologically confirmed breast cancerXx_NEWLINE_xXPatients with histologically or cytologically documented, unresectable, Stage IV transitional cell carcinoma of the urothelium who have not been previously treated with first-line chemotherapy.Xx_NEWLINE_xXHistologically confirmed diagnosis of primary non small lung cancer (NSCLC) on predominantly non-squamous histologyXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of NSCLC that is:Xx_NEWLINE_xXPatients must have histologically confirmed diagnosis of osteosarcoma or Ewing sarcoma by central review, except if the diagnosis was already confirmed by the RRePS (Réseau de Référence en Pathologie des Sarcomes et des Tissus Mous et des Viscères) networkXx_NEWLINE_xXAdvanced malignancies (except leukemias), histologically proven at diagnosis; Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROSXx_NEWLINE_xXHistologically confirmed prostate cancerXx_NEWLINE_xXPatients with a histologically-confirmed, advanced solid malignancy for which pembrolizumab is approved (Parts C and D)Xx_NEWLINE_xXMust have a confirmed diagnosis of active MMXx_NEWLINE_xXHistologically or cytologically confirmed advanced or metastatic RCC with clear cell componentXx_NEWLINE_xXHistologically-confirmed diagnosis of high risk non-muscle-invasive (T1, high grade Ta and / or carcinoma in situ [CIS]) transitional cell carcinoma of the bladder (mixed histology tumors allowed if transitional cell histology is predominant histology).Xx_NEWLINE_xXPatients must have a histologically or cytologically confirmed solid malignancy that is metastatic or unresectable for which standard curative or palliative treatments do not exist or are no longer effective\r\n* Hepatocellular carcinoma (HCC) patients are not required to have histologically or cytologically confirmed malignancy, patients are considered eligible based on tumor markers and/or imaging assessment\r\n* Patients with the following tumor types will be excluded from the normal and mild cohorts:\r\n** Pancreatic cancer patients\r\n** Colorectal cancer patients \r\n** BRAF V600E melanoma patients who have failed BRAF inhibitors\r\n*** Note: Patients with pancreatic cancer, colorectal cancer, and BRAF V600E melanoma patients who have failed BRAF inhibitors are allowed to enroll in the moderate and severe cohorts provided the patients: 1) sign a separate consent form which outlines the extremely limited activity observed in prior studies, and 2) are consented to the study by a protocol-specified designee who is not their longitudinal oncologistXx_NEWLINE_xXPatients must have histologically confirmed advanced RCC (any histology); collecting duct tumors and tumors originating from the renal pelvis or upper urinary tract are considered of urothelial origin and are excluded from this protocolXx_NEWLINE_xXHistologically and/or cytologically confirmed, non-small cell lung cancer (NSCLC) of adenocarcinoma histology at the time of initial diagnosis.\r\na) Mixed tumors will be categorized by the predominant cell type; (Note: If small cell elements are present the patient is ineligible)\r\nb) Known mutational status of KRAS and BRAF oncogenes.\r\nc) For patients in whom mutational testing result is unknown or unavailable from a prior test, KRAS and BRAF testing will be performed (at a CLIA-certified laboratory) using an archived or fresh biopsy as per Standard of Care, prior to enrollment.Xx_NEWLINE_xXARM B COHORT 2: Patients must have a histologically confirmed diagnosis of head and neck (squamous cell) carcinomaXx_NEWLINE_xXARM B COHORT 3: Patients must have a histologically confirmed diagnosis of non-small cell lung cancerXx_NEWLINE_xXARM C COHORT 4: Patients must have a histologically or cytologically proven diagnosis of advanced (unresectable or metastatic) gallbladder cancer or cholangiocarcinoma and be candidates for first line therapy with gemcitabine and cisplatinXx_NEWLINE_xXPHASE I: Histologically confirmed advanced RCC of any subtypeXx_NEWLINE_xXHistologically documented diagnosis of solid tumorXx_NEWLINE_xXFor subjects in the every 2 week and every 1 week dosing cohorts histologically or cytologically documented diagnosis of urothelial carcinoma, melanoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, or any solid tumor with high microsatellite instability status (MSI-high)Xx_NEWLINE_xXHistologically confirmed breast cancerXx_NEWLINE_xXPatients with histologically confirmed, advanced or metastatic cancer for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXNewly diagnosed histologically or cytologically confirmed operable invasive breast cancer defined as cT1 or T2, N0-1, and M0Xx_NEWLINE_xXHistologically or cytologically confirmed advanced solid tumor malignancy, refractory or relapsed from prior therapy, or for whom no alternative therapy is availableXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of solid malignant tumor.Xx_NEWLINE_xXPatients must have histologically confirmed stage IV non-squamous histology non-small cell lung cancerXx_NEWLINE_xXPatients must have histologically or cytologically confirmed at least 1 thyroid nodule that is >= 1 cm but =< 4 cm measured in greatest dimension and confirmed by the Laboratory of Pathology, National Cancer Institute (NCI) or confirmed by the pathology laboratory of enrolling institution:\r\n* Indeterminate thyroid biopsy per Bethesda System for reporting thyroid cytopathology with BRAF V600E mutation or RET/positron emission tomography (PET) rearrangement\r\n* Cytologically or histologically suspicious or confirmed PTC per Bethesda System for reporting thyroid cytopathologyXx_NEWLINE_xXHistologically confirmed metastatic or recurrent HER2-negative (via IHC or FISH per ASCO/CAP guidelines 2013) breast cancer or histologically confirmed metastatic solid tumorXx_NEWLINE_xXHistologically or cytologically confirmed incurable HNSCC of the oral cavity, oropharynx, larynx, hypopharynx, and/or level 1-3 neck node with non-cutaneous squamous cell carcinoma (SCC) and unknown primary; “incurable” is defined as metastatic disease or a local or regional recurrence in a previously irradiated site that is unresectable (or patient declines resection)Xx_NEWLINE_xXHistologically confirmed cancer by a Mount Sinai pathologistXx_NEWLINE_xXPatients must have newly diagnosed (i.e., within 5 weeks), histologically or cytologically confirmed glioblastoma multiformeXx_NEWLINE_xXCurrent histologically transformed disease.Xx_NEWLINE_xXHistologically confirmed diagnosis of cancer as per the cohort specificationsXx_NEWLINE_xXHistologically or cytologically confirmed hepatocellular carcinoma (HCC) or clinical diagnosis by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic subjects is requiredXx_NEWLINE_xXHistologically confirmed diagnosis of epithelial cancer; subject must have a measurable disease for enrollment considerationXx_NEWLINE_xXPatients with histologically or cytologically confirmed diagnosis of refractory metastatic solid tumor for whom no other standard treatment options are availableXx_NEWLINE_xXNon-small cell lung cancer (NSCLC), histologically and/or cytologically provenXx_NEWLINE_xXArm 1: histologically or cytologically confirmed solid tumors that are advanced that gemcitabine-based treatment is considered a clinically appropriate optionXx_NEWLINE_xXArm 3: histologically or cytologically confirmed solid tumors that are advanced that gemcitabine plus cisplatin treatment is considered a clinically appropriate optionXx_NEWLINE_xXHistologically- or cytologically-confirmed CRCXx_NEWLINE_xXPatients with histologically or cytologically confirmed metastatic clear cell RCC who are eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy; diagnosis must be confirmed by pathologist review of screening biopsy; the determination of resectability will ultimately lie in the clinical judgment of the urologist and medical oncologist involved in the care of the patientXx_NEWLINE_xXParticipant has a prior histologically-confirmed diagnosis of a grade III or IV glioma, or has a prior histologically-confirmed diagnosis of a grade II glioma and now has radiographic progression consistent with a grade III or IV malignant glioma (MG) after completing standard therapyXx_NEWLINE_xXHistologically confirmed diagnosis of squamous cell carcinoma of the larynx, stages III, IVa, or IVb, p16-negative on immunohistochemistryXx_NEWLINE_xXHistologically-confirmed diagnosis of a grade III or IV glioma (including glioblastoma, anaplastic astrocytoma, gliosarcoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma), or has a prior, histologically-confirmed, diagnosis of a grade II glioma and now has radiographic findings consistent with a high-grade glioma (grade III or IV)Xx_NEWLINE_xXPatients must have a previously histologically or cytologically confirmed high grade glioma (astrocytic or oligodendroglial supratentorial tumors grade 3 or 4) that has been previously treated with fractionated radiation therapy and now shows evidence of recurrenceXx_NEWLINE_xXPatient must have newly diagnosed, histologically confirmed GBMXx_NEWLINE_xXHistologically confirmed diagnosis of squamous cell carcinoma of the oropharynx, stage IVa, p16-positive on immunohistochemistry (determination of HPV status using p16 as surrogate is standard of care)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary, follicular, or poorly differentiated subtypes and their respective variants); confirmation of thyroid carcinoma will be done at Memorial Sloan-Kettering (MSK)Xx_NEWLINE_xXHas a histologically- or cytologically-confirmed metastatic solid tumor for which there is no available therapy which may convey clinical benefit. Part E: Has advanced malignant melanoma.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed (at original diagnosis or subsequent recurrence or progression) solid tumor that is metastatic, unresectable, progressive, or recurrent, and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXPatient must have a histologically or cytologically confirmed diagnosis of unresectable stage III or IV melanoma; patient may not have a diagnosis of uveal melanomaXx_NEWLINE_xXHistologically confirmed AML by hematopathology review performed within four weeks prior to study entryXx_NEWLINE_xXPatients must have histologically- or cytologically-confirmed diagnosis of KRAS or NRAS mutation-positive malignancy that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective; patients must have activating mutations affecting codons 12, 13, 61, or 146 as determined in a Clinical Laboratory Improvement Amendments (CLIA)-certified lab to be eligible for this studyXx_NEWLINE_xXHistologically-confirmed primary uveal melanomaXx_NEWLINE_xXPatients must have histologically or cytologically confirmed glioblastoma multiforme, anaplastic astrocytoma, or gliosarcomaXx_NEWLINE_xXPatients do not need a histologically proven diagnosis of brain metsXx_NEWLINE_xXHistologically or cytologically-confirmed Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, or osteosarcomaXx_NEWLINE_xXPatients must have pathologically confirmed GISTXx_NEWLINE_xXPatients must have histologically or cytologically-confirmed diagnosis of progressive or recurrent malignancy as follows:Xx_NEWLINE_xXHistologically confirmed gliomaXx_NEWLINE_xXPatients must have histologically confirmed soft tissue sarcoma with evidence of metastatic or unresectable diseaseXx_NEWLINE_xXHistologically confirmed HER2-positive metastatic breast cancerXx_NEWLINE_xXHistologically confirmed non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXHistologically confirmed diagnosis of invasive cervical cancerXx_NEWLINE_xXParticipants must have histologically confirmed primary cancer of the uterus or cervix with histologically confirmed metastasis to one or more parametrial, pelvic, or para-aortic nodes prior to enrollment; participants diagnosed at other institutions must have pathology reviewed and confirmed at Massachusetts General Hospital (MGH) or another Dana-Farber (DF)/Harvard Cancer Center (HCC) institutionXx_NEWLINE_xXPhase Ib: Patient must have histologically or cytologically documented solid tumor malignanciesXx_NEWLINE_xXHistologically confirmed diagnosis of metastatic or unresectable soft tissue sarcoma, excluding gastrointestinal stromal tumors, Kaposi‘s sarcoma, Ewing‘s family of tumors, and embryonal or alveolar rhabdomyosarcomaXx_NEWLINE_xXPatient must have suspected intrahepatic or hilar cholangiocarcinoma with minimal extrahepatic disease; diagnosis must be histologically or cytologically confirmed for continued treatment on study after pump placementXx_NEWLINE_xXThe diagnosis of GBM or anaplastic astrocytoma must be histologically confirmedXx_NEWLINE_xXPatients with histologically proven glioblastomas or gliosarcomas that express EGFRvIII as assessed by immunohistochemistry (IHC) or polymerase chain reaction (PCR) confirmed by the National Cancer Institute (NCI) Laboratory of PathologyXx_NEWLINE_xXHistologically confirmed diagnosis of chordoma or chondrosarcomaXx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of supratentorial high-grade glioma or supratentorial ependymoma that is recurrent, progressive or refractoryXx_NEWLINE_xXParticipants with histologically or cytologically confirmed extensive-stage small cell lung cancer (SCLC) with progressive disease after at least one platinum-based chemotherapeutic regimen and with evaluable or measurable diseaseXx_NEWLINE_xXPatients must have histologically confirmed malignancy with brain metastases and are being recommended palliative WBRTXx_NEWLINE_xXHistologically confirmed diagnosis of prostate cancer.Xx_NEWLINE_xX50% or less histologically or cytologically-proven ocular melanoma metastases in the parenchyma of the liver.Xx_NEWLINE_xXPart 1a: Subjects with histologically or cytologically confirmed advanced or metastatic solid tumors that have failed prior standard therapy (including subject refusal or intolerance).Xx_NEWLINE_xXhistologically or cytologically confirmed diagnosis of thyroid cancer (cohort 1) or squamous head and neck cancer (cohort 2) for which there is no curative therapy available.Xx_NEWLINE_xXAll subjects must have history of histologically confirmed malignancy; brain biopsy is not required unless diagnosis is judged to be in doubt by the treating physicianXx_NEWLINE_xXHistologically positive marginsXx_NEWLINE_xXHistologically confirmed diagnosis of NSCLCXx_NEWLINE_xXHistologically or cytologically confirmed, or clinically diagnosed based on currently accepted standards, cancer metastatic to the liver or HCC that is not amenable at the time of enrollment to resection, transplant or other potentially curative therapy.Xx_NEWLINE_xXHistologically or cytologically documented diseaseXx_NEWLINE_xXPhase II: patients must have histologically verified tumor at initial diagnosis and radiologically or histologically confirmed status at inclusion as indicated in the following: neuroblastoma, osteosarcoma, rhabdomyosarcoma or Ewing sarcoma.Xx_NEWLINE_xXDiagnosis: Histologically confirmed rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) (Grade 2 or 3), or Ewing sarcoma (EWS) which is relapsed or refractory (failed front line therapy)Xx_NEWLINE_xXPathologically (histologically or cytologically) confirmed diagnosis of esophageal squamous cell carcinoma (ESCC)Xx_NEWLINE_xXHave histologically- or cytologically-confirmed diagnosis of Stage IV NSCLC and meet the corresponding requirements for the cohort of the study they will enroll into;Xx_NEWLINE_xXHistologically or cytologically confirmedXx_NEWLINE_xXHistologically confirmed diagnosis of HCCXx_NEWLINE_xXHistologically or cytologically confirmed (patients with mixed histologies are required to have a dominant transitional cell pattern.)Xx_NEWLINE_xXHistologically confirmed diagnosis of one of the following cancers: melanoma (including mucosal and/or ocular), bladder/urothelial, non-small cell lung cancer, pancreatic adenocarcinoma, breast, colorectal, gastric, esophageal, renal cell, hepatic, ovarian, head and neck, and cholangiocarcinomaXx_NEWLINE_xXAdult men and women (? 18 years of age) with histologically confirmed diagnosis of metastatic and/or advanced solid tumors not amenable to curative treatment by surgery.Xx_NEWLINE_xXPatients must have histologically confirmed solid malignancy or lymphoma that is metastatic or unresectableXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of stage III/IV Non-Small Cell Lung Cancer (NSCLC)Xx_NEWLINE_xXHistologically or cytologically confirmed metastatic or recurrent tumor typesXx_NEWLINE_xXHistologically or cytologically confirmed advanced (unresectable and/or metastatic) HCCXx_NEWLINE_xXConfirmed diagnosis of refractory/relapsed AML or high-risk MDSXx_NEWLINE_xXHistologically confirmed glioblastoma or gliosarcoma in 1st, 2nd or 3rd relapse.Xx_NEWLINE_xXCytologically or histologically confirmed non squamous NSCLC Stage IV (including pleural effusion).Xx_NEWLINE_xXPatients with histologically confirmed GBM and/or other glioma subtypes at the time of diagnosis or prior relapse.Xx_NEWLINE_xXHistologically or cytologically documented non-small cell lung cancer (NSCLC) .Xx_NEWLINE_xXHistologically confirmed prostate cancer, currently with progressive diseaseXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed squamous cell carcinoma of the oropharynx or unknown primary that is high risk human papillomavirus (HPV) positive as determined by p16 immunohistochemistry (IHC) testing and/or HPV in situ hybridization (ISH) / polymerase chain reaction (PCR)Xx_NEWLINE_xXHistologically confirmed diagnosis of urothelial carcinoma of the bladder, urethra, ureter, or renal pelvisXx_NEWLINE_xXHistologically confirmed diagnosis of ACC according to Weiss system by a national reference pathologist who has to be nominated before study initiation.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed malignant mesothelioma for which they have received pemetrexed in combination with cisplatin as part of chemotherapeutic regimen.Xx_NEWLINE_xXHistologically proven rectal cancerXx_NEWLINE_xXHistologically confirmed malignant solid tumor and not a candidate for known regimens or protocol treatments of higher efficacy or priorityXx_NEWLINE_xXMust have histologically or cytologically confirmed diagnosis of MDS according to WHO classification that meets IPSS low to intermediate-1 risk criteria.Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of Ewing sarcoma and have progressed on or after standard therapies.Xx_NEWLINE_xXPatients must have histologically or cytologically documented locally advanced/inoperable or metastatic urothelial bladder carcinoma (UBC), including renal pelvis, ureters, urinary bladder, and urethra\r\n* Note: mixed histology tumors allowed if predominant histology is urothelial carcinoma\r\n* Note: small cell or neuroendocrine carcinoma is not allowed if predominantXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of advanced cancer in patients with solid tumors that are refractory to standard treatment, or for whom no effective therapy exists.Xx_NEWLINE_xXPathologically (histologically or cytologically) proven diagnosis of recurrent/persistent ovarian, or peritoneal endometrioid/clear cell carcinoma, OR recurrent/persistent low grade (grade 1 or 2) endometrioid endometrial adenocarcinoma; primary ovarian tumors must be at least 50% endometrioid/clear cell morphology, or have histologically documented recurrence with at least 50% endometrioid/clear cell morphology; appropriate tissue sections must be available for histologic evaluation for central pathology review by National Research Group (NRG) OncologyXx_NEWLINE_xXHistologically or cytologically confirmed solid tumors or hepatocellular carcinoma with known disease progression.Xx_NEWLINE_xXPatients with histologically-confirmed Tis, T1a, or T4 tumorsXx_NEWLINE_xXHistologically- or cytologically-confirmed mCRC.Xx_NEWLINE_xXHistologically confirmed advanced solid tumors with measurable lesions per RECIST v1.1 that are considered nonamenable to surgery or other curative treatments or procedures.Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of Stage IV non-squamous NSCLC.Xx_NEWLINE_xXExpansion cohort (HCC): histologically or cytologically confirmed diagnosis of hepatocellular carcinoma who are Child-Pugh class A and who were previously treated with sorafenib or refused sorafenibXx_NEWLINE_xXHistologically confirmed Ewing's Sarcoma Family of Tumors (ESFT).Xx_NEWLINE_xXHistologically or cytologically confirmed BRAF- or MEK-mutated melanomaXx_NEWLINE_xXWomen with biopsy confirmed high grade cervical intraepithelial lesions (diagnosis confirmed by\r\npositive p16 immunohistochemistry staining) within 12 weeks of baseline visitXx_NEWLINE_xXA histologically or cytologically confirmed diagnosis of stage IV NSCLCXx_NEWLINE_xXHistologically confirmed diagnosis of a CD20+ B-cell malignancy;Xx_NEWLINE_xXHistologically-confirmed metastatic CRCXx_NEWLINE_xXPathologically confirmed diagnosis of liposarcoma; all subtypes are eligibleXx_NEWLINE_xXHistologically confirmed squamous cell carcinoma of the head and neck including the oral cavity, oropharynx, hypopharynx or larynx, excluding nasopharynxXx_NEWLINE_xXHave histologically or cytologically confirmed non-small cell lung cancerXx_NEWLINE_xXPatients must have histologically or cytologically confirmed carcinoma of the prostate (CaP); CaP can be recurrent disease after definitive therapy (radical prostatectomy or radiation therapy) for localized CaP, or metastatic CaPXx_NEWLINE_xXPatients with histologically confirmed carcinoma of the female breast with any or unknown hormone receptors (HRs)/HER2 statusXx_NEWLINE_xXPatients must have newly diagnosed (i.e., within 4 weeks), histologically or cytologically confirmed non-small cell lung cancerXx_NEWLINE_xXPatients must have histologically confirmed progressive brain metastases from melanoma, or recurrent/progressive malignant glioma (glioblastoma, anaplastic glioma), for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXPatients must have histologically or cytologically confirmed metastatic urothelial carcinoma; urothelial cancer derived from the bladder, ureter or upper tract is permittedXx_NEWLINE_xXHistologically proven diagnosis of salivary cancer by central pathology reviewXx_NEWLINE_xXFor Dose Escalation Cohort: Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXHistologically confirmed plasmacytoma amenable for biopsyXx_NEWLINE_xXPathologically (histologically or cytologically) or radiographically-proven (based on the American Association for the Study of Liver Diseases [AALSD] criteria) unresectable or locally recurrent hepatocellular cancer prior to registrationXx_NEWLINE_xXPart 2 patients must have histologically confirmed glioblastoma or gliosarcomaXx_NEWLINE_xXParticipant must have histologically or cytologically confirmed advanced or metastatic Small Cell Lung Cancer (SCLC) with documented first disease progression during or following front-line platinum-based systemic regimenXx_NEWLINE_xXFor the dose escalation cohort, patients must have histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXHistologically or cytologically-confirmed diagnosis of HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed metastatic endometrial cancer; eligible histologies for the experimental cohort are: endometrioid or serous; eligible histologies for the exploratory cohort are: carcinosarcoma, clear cell, mixed, adenosquamous and any other rare sub-type of endometrial cancerXx_NEWLINE_xXPatients must have histologically-proven GBMXx_NEWLINE_xXPatients must have histologically confirmed urothelial carcinoma that is advanced or metastaticXx_NEWLINE_xXPatients must have histologically confirmed grade 2 or 3 tumors by the French Federation of Cancer Centers Sarcoma Group (FNCLCC) sarcoma grading systemXx_NEWLINE_xXPathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), hypopharynx or larynxXx_NEWLINE_xXSubjects with histologically confirmed diagnosis of recurrent germ cell tumorXx_NEWLINE_xXOn primary diagnosis, patients must have had histologically confirmed adenocarcinoma of the colon or rectum; metastasis or recurrence do not need to be histologically confirmedXx_NEWLINE_xXPathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), larynx, or hypopharynxXx_NEWLINE_xXARM B: Histologically or cytologically confirmed solid tumor with subcutaneous/cutaneous lesions that is refractory (RECIST or with unequivocal clinical progression of disease) to or intolerant to standard therapyXx_NEWLINE_xXPatients must have histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable, for which standard curative or palliative measures do not exist or are no longer effective, and for which there is expectation of response to the combination of carboplatin/paclitaxel (i.e., lung, ovarian, breast, melanoma, head and neck, endometrial, urothelial, testicular, esophageal, carcinoma of unknown primary); for indications not listed, eligibility based on disease must be verified by the principal investigator before they are consideredXx_NEWLINE_xXPatients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXPatients must have histologically or cytologically confirmed small cell lung cancer whose disease has relapsed or progressed after >= 1 prior therapy, one of which must have been a platinum doublet; pathology confirmation must be done at Sidney Kimmel Comprehensive Cancer Center (SKCCC) or at the local participating siteXx_NEWLINE_xXPatients must have histologically and/or cytologically confirmed solid tumors or B cell lymphoma that are metastatic or unresectable and for which standard treatment options do not exist; patients with hepatocellular carcinoma are eligible without pathological diagnosis if diagnosed on the basis of blood work and imagingXx_NEWLINE_xXHistologically or cytologically confirmed advanced RCC with predominantly clear cell subtypeXx_NEWLINE_xXPatients with histologically or cytologically confirmed metastatic NETs of any origin of low or intermediate grade (Part 1)Xx_NEWLINE_xXPatients with histologically confirmed unresectable or metastatic pancreatic (p)NETs of low or intermediate grade; high-grade tumors or tumors with small cell histology will be excluded (Part 2)Xx_NEWLINE_xXParticipants must have stage IV, locally advanced or metastatic (T4b, any N; or any T, N2-3) urothelial bladder cancer or TCC arising in another location of the urinary tract, including urethra, ureter, and renal pelvis; the diagnosis must be histologically or cytologically confirmed; mixed histologies are permitted as long as TCC is the major component (i.e. > 50% of the pathologic specimen); pure or predominant squamous cell carcinomas or adenocarcinomas are not permittedXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of extensive-stage small cell lung cancer with no prior systemic treatmentXx_NEWLINE_xXHistologically confirmed high grade serous or endometrioid ovarian, peritoneal or fallopian tube malignancy that is metastatic and for which curative measures do not exist; pathology must be reviewed and confirmed at Mayo Clinic Department of Pathology; the histology can be confirmed from tissue that was taken at the time of diagnosis; a biopsy at the time of recurrence prior to enrollment on study is not requiredXx_NEWLINE_xXHistologically confirmed melanoma of cutaneous primary; metastatic melanoma from unknown primary are allowedXx_NEWLINE_xXIn dose escalation, patients must have histologically or cytologically confirmed metastatic disease from any solid tumor; in dose expansion, patients must have histologically or cytologically confirmed metastatic melanoma, renal cell carcinoma, ovarian cancer, or colorectal cancerXx_NEWLINE_xXHistologically confirmed solid tumor (leukemia and lymphoma are excluded)Xx_NEWLINE_xXHistologically proven GBMXx_NEWLINE_xXSubjects must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXPatients must have histologically documented (confirmed at the Laboratory of Pathology, National Cancer Institute [NCI]), relapsed solid tumor malignancy or Hodgkin's disease/non-Hodgkin lymphoma that is metastatic or unresectable for which standard curative measures do not exist, or are associated with minimal patient survival benefitXx_NEWLINE_xXSubjects having histologically and/or cytologically confirmed non-haematological\n             malignancy that is metastatic or unresectable and for which standard curative or\n             palliative treatment does not exist or is no longer effectiveXx_NEWLINE_xXHistologically- or cytologically- confirmed solid tumor (except melanoma) that is\n             metastatic or unresectableXx_NEWLINE_xXCytologically or histologically confirmed evidence of transitional cell carcinoma of bladder, renal pelvis, ureter or urethraXx_NEWLINE_xXPatients must have histologically confirmed glioblastoma that is progressive or recurrent following radiation therapy and temozolomideXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of biliary tract adenocarcinoma/ cholangiocarcinoma (including primary intra- and extrahepatic diseases); pathologic confirmation may be made from the primary or a metastatic siteXx_NEWLINE_xXPatients must have histologically or cytologically confirmed neuroendocrine carcinoma of the gastrointestinal (GI) tract; patients with unknown origin for the neuroendocrine carcinoma in which a gastroenteropancreatic origin is suspected (per pathologist or investigator discretion) will be eligible for the studyXx_NEWLINE_xXMust have histologically confirmed diagnosis of MPNSTXx_NEWLINE_xXSubjects must have histologically or cytologically confirmed previously treated unresectable mesothelin expressing advanced lung adenocarcinoma (stage IIIB or IV) as confirmed by the Laboratory of Pathology, National Cancer Institute (NCI)Xx_NEWLINE_xXPatients without histologically or cytologically confirmed node metastases or any other metastasesXx_NEWLINE_xXFemale with histologically confirmed breast cancerXx_NEWLINE_xXPatients must have a histologically or cytologically confirmed, previously untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynxXx_NEWLINE_xXPatients must have histologically confirmed squamous cell carcinoma, undifferentiated carcinoma, or poorly differentiated carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx with no evidence of distant metastasis; biopsy sampling of primary tumor with pathology report documentation of confirmed diagnostic tissue type is required; patients should be evaluated by a radiation oncologist, medical oncologist and otolaryngologist prior to enrolling on studyXx_NEWLINE_xXPatients must have histologically or cytologically confirmed non-central nervous system primary breast or non-small cell lung cancerXx_NEWLINE_xXPatients must have a histologically/cytologically confirmed diagnosis of recurrent glioblastoma or an advanced solid tumor in which bevacizumab has shown benefit in specific disease population and for which standard or curative measures do not exist or are no longer effectiveXx_NEWLINE_xXPatients with a histologically-confirmed diagnosis of melanoma who have imaging findings suggestive of 1 to 4 brain metastasesXx_NEWLINE_xXPatient has had a prior, histologically-confirmed, diagnosis of a grade III or IV glioma (including glioblastoma, anaplastic astrocytoma, gliosarcoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma), or has a prior, histologically-confirmed, diagnosis of a grade II glioma and now has radiographic findings consistent with a high-grade glioma (grade III or IV)Xx_NEWLINE_xXPatients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effectiveXx_NEWLINE_xXStudy participants must have histologically or cytologically confirmed unresectable or metastatic malignant melanomaXx_NEWLINE_xXAmerican Joint Committee on Cancer (AJCC) stage III/IVB, excluding T1N1, histologically or cytologically confirmed squamous cell carcinoma or undifferentiated carcinoma of the head and neck; patients should not have distant metastasis; primary sites include: oropharynx, hypopharynx, larynxXx_NEWLINE_xXHistologically or cytologically confirmed uveal melanoma that is metastatic or unresectable; if histologic or cytologic confirmation of the primary is not available, confirmation of the primary diagnosis of uveal melanoma by the treating investigator can be clinically obtained, as per standard practice for uveal melanoma; pathologic confirmation of diagnosis will be performed at the participating siteXx_NEWLINE_xXHistologically confirmed infiltrating carcinoma of the breast (stage I-III)Xx_NEWLINE_xXHistologically or cytologically confirmed (from the primary lesion and/or regional lymph nodes) squamous cell carcinoma of the oropharynx, hypopharynx, or larynx that has not been previously treated or resected; patients with unresectable oral cavity cancers are also eligible; human papilloma virus (HPV) testing is required, although both HPV-positive and -negative patients are eligibleXx_NEWLINE_xXPatients must have histologically or cytologically confirmed peritoneal surface malignancies from primary appendiceal tumorsXx_NEWLINE_xXPatients must have histologically or cytologically confirmed peritoneal surface malignancies from primary colorectal and appendiceal tumorsXx_NEWLINE_xXPatient must have histologically or cytologically confirmed oral cavity squamous cell carcinoma of stage 2, 3, 4a, or 4b (by American Joint Committee on Cancer [AJCC] 7th edition [ed.])Xx_NEWLINE_xXPatients must have FDG-avid (maximum SUV >= 4.0) (from PET scan of any date, any scanner) and histologically or cytologically proven non-small cell lung cancerXx_NEWLINE_xXPatients must have histologically or cytologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal (GE) junction\r\n* For the phase I study, patients can have disease that is deemed resectable or unresectable\r\n* For the phase II study, patients must have disease that is resectableXx_NEWLINE_xXPatients must have histologically-proven recurrent and/or metastatic squamous cell carcinoma of the head and neck that is unresectable; patients in the phase II portion of the trial must have measurable diseaseXx_NEWLINE_xXPatients must have histologically confirmed renal cell carcinoma (of any subtype) containing any sarcomatoid features; there must be histologic confirmation by the treating center of either the primary or metastatic lesionXx_NEWLINE_xXPatient must have histologically or cytologically confirmed diagnosis of malignant pleural mesothelioma; surgical resection must not be plannedXx_NEWLINE_xXPatients with chemotherapy (chemo)-sensitive histologically confirmed NHL will be eligible for this treatment protocol contingent on histologic subclassificationXx_NEWLINE_xXPatients with hematologic malignancies, myelodysplasia, or myeloproliferative disorders; the diagnosis must be histologically confirmed by the Laboratory of Pathology of the National Cancer Institute (NCI) or Hackensack (there will be no central pathology review)Xx_NEWLINE_xXAge ? 18 years with histologically confirmed diagnosis of melanoma and stage IIIB to IVM1c for whom surgery is not recommended.Xx_NEWLINE_xXHas one of the following histologically confirmed tumors: (NOTE: Evidence of diagnostic pathology of original biopsy confirmed by a CLIA/CAP certified laboratory must be available)Xx_NEWLINE_xXHas one of the following histologically confirmed tumors:Xx_NEWLINE_xXHistologically confirmed, previously untreated (treatment-naive) RCCXx_NEWLINE_xXParticipants with Histologically or cytologically confirmed Stage III non-small cell lung cancer (NSCLC).Xx_NEWLINE_xXHistologically confirmed recurrent or metastatic colorectal cancerXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of relapsed or refractory advanced or metastatic malignancies:Xx_NEWLINE_xXPart 2: histologically confirmed disease in specific tumor typesXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of malignancy with demonstrated progression of a solid tumor (non-lymphoma) with no alternative standard-of-care therapeutic option (certain exceptions may apply).Xx_NEWLINE_xXSubjects with histologically or cytologically confirmed NSCLC, MEL (including I/O relapsed MEL or I/O refractory MEL), CRC, SCCHN, ovarian cancer, recurrent B cell NHL or HL, or glioblastomaXx_NEWLINE_xXHistologically or cytologically confirmed transitional cell carcinoma of the genitourinary tractXx_NEWLINE_xXMust have histologically or cytologically confirmed diagnosis of HCC (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible).Xx_NEWLINE_xXHistologically or cytologically confirmed carcinoma of the breastXx_NEWLINE_xXHistologically confirmed, advanced, predominantly clear cell renal cell carcinoma (RCC).Xx_NEWLINE_xXFor the phase I portion, patients must have histologically and/or cytologically confirmed malignant solid tumor that is refractory to standard therapiesXx_NEWLINE_xXHas a histologically or cytologically confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial carcinoma of the renal pelvis, ureter [upper urinary tract], bladder, or urethra. Both transitional cell and mixed transitional/non- transitional cell histologies are allowed, but transitional cell carcinoma must be the predominant histology.Xx_NEWLINE_xXHave histologically or cytologically confirmed melanomaXx_NEWLINE_xXPatients with a histologically or cytologically confirmed diagnosis of breast cancer; patients must have metastatic HER2 positive (+) diseaseXx_NEWLINE_xXSubject has definitive histologically or cytologically confirmed Stage IIIB or IV NSCLC.Xx_NEWLINE_xXSubject has a definitive histologically or cytologically confirmed diagnosis of HER2(-) metastatic breast cancer.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed head and neck squamous cell cancer (HNSCC) including paranasal sinus cancers but excluding nasopharyngeal carcinomasXx_NEWLINE_xXSubjects with histologically or cytologically confirmed advanced solid tumors or lymphoma that is metastatic or unresectable, and for whom standard life-prolonging measures are not available. Specific tumor types that will be selected for study in Phase 2 are detailed in the protocol.Xx_NEWLINE_xXPatients with stage IV or recurrent/metastatic histologically confirmed non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXHistologically- or cytologically-confirmed malignancy that is metastatic or unresectable and for which standard measures do not exist or are no longer effective (DEP) or a histologically confirmed diagnosis of PTCL based on pathology review at the local institution, using the most recent edition of the WHO Classification, relapsed or refractory disease after at least one prior systemic anticancer regimen (EXP in PTCL)Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neckXx_NEWLINE_xXHistologically and/or cytologically confirmed and radiographically measurable KRAS and NRAS wild-type adenocarcinoma of the colon or rectum that is metastatic and/or unresectable; subjects must have been treated with a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan and bevacizumab or have contraindication to such treatmentXx_NEWLINE_xXHistologically confirmed solid tumor malignancy with greater than 5 sites of metastatic disease detected on cross-sectional imagingXx_NEWLINE_xXPatients with histologically confirmed intrahepatic, perihilar or extra-hepatic CCA.Xx_NEWLINE_xXHistologically confirmed Ewing sarcomaXx_NEWLINE_xXHistologically confirmed unresectable soft tissue sarcoma (i.e., non-GIST, non-adipocytic) that has progressed following treatment with chemotherapy. Prior pazopanib is allowed if the drug was not discontinued for toxicity ( Phase 1 only)Xx_NEWLINE_xXConfirmed histological diagnosis of recurrent GBM or gliosarcomaXx_NEWLINE_xXPatients must have histologically or cytologically confirmed renal cell carcinoma (clear cell or non-clear cell allowed, but collecting duct or medullary carcinomas excluded); patients must be considered pathologically either intermediate high risk or very high risk; patients must not have a history of distant metastases; patients with microvascular invasion of the renal vein of any grade or stage (as long as M0) are also eligibleXx_NEWLINE_xXPart 1: Subjects with histologically or cytologically confirmed advanced or metastatic solid tumors that have failed prior standard therapy (disease progression; subject refusal or intolerance is also allowable).Xx_NEWLINE_xXSubjects with histologically or cytologically confirmed NSCLC:Xx_NEWLINE_xXHave histologically confirmed microsatellite stable (MSS) CRC.Xx_NEWLINE_xXHistologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx.Xx_NEWLINE_xXHistologically or cytologically confirmed melanoma.Xx_NEWLINE_xXHistologically or cytologically confirmed urothelial carcinoma of the renal pelvis, ureter, urinary bladder, or urethra that is transitional cell or mixed transitional/nontransitional (predominantly transitional) cell type.Xx_NEWLINE_xXHistologically confirmed diagnosis of Renal Cell Carcinoma with a documented clear cell component (ccRCC)Xx_NEWLINE_xXBased on RECIST v1.1 criteria on current nivolumab treatment (prior to initiation of this study), has a best response of confirmed stable disease (SD) or confirmed progressive disease (PD). Confirmed SD or confirmed PD refers to a response that is confirmed by a 2nd scan which is at least 4 weeks apart from the previous scan.Xx_NEWLINE_xXCohort A (clear cell RCC cohort) participant must have histologically confirmed diagnosis of clear cell RCC or RCC with clear cell component (with or without sarcomatoid features).Xx_NEWLINE_xXCohort B (non-clear cell RCC cohort) participant must have histologically confirmed diagnosis of non-clear cell RCC (with or without sarcomatoid features). Participants with tumors that have a component of clear cell histology are not eligible for inclusion in Cohort B.Xx_NEWLINE_xXHistologically confirmed glioblastoma. A local pathology report constitutes adequate documentation of histology for study inclusion. Patients with an initial diagnosis of a lower-grade glioma are eligible if a subsequent biopsy was determined to be glioblastoma.Xx_NEWLINE_xXSubject must have histologically or cytologically confirmed solid tumor;Xx_NEWLINE_xXHistologically confirmed hepatocellular carcinoma not amenable for management with curative intent by surgery or local therapeutic measure;Xx_NEWLINE_xXHistologically or cytologically confirmed prostate cancer (individuals with primary neuroendocrine carcinoma of prostate are excluded)Xx_NEWLINE_xXSubjects must have histologically or cytologically confirmed advanced solid tumor for recurrent or metastatic disease.Xx_NEWLINE_xXHas a histologically-confirmed or cytologically confirmed diagnosis of stage IV nonsquamous NSCLC.Xx_NEWLINE_xXHistologically-confirmed diseaseXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors that have a NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alteration.Xx_NEWLINE_xXDiagnosis - Dose Expansion Phase: Histologically or cytologically confirmed advanced RCC with a component of clear cell subtypeXx_NEWLINE_xXDiagnosis with confirmed histology of one or more of the following:Xx_NEWLINE_xXParticipant must have cytologically or histologically confirmed Non-small Cell Lung Cancer (NSCLC).Xx_NEWLINE_xXHas histologically confirmed diagnosis of RCC with clear cell component with or without sarcomatoid features.Xx_NEWLINE_xXHistologically proven MCCXx_NEWLINE_xXHistologically or cytologically confirmed metastatic breast cancerXx_NEWLINE_xXPatients with histologically/cytologically confirmed advanced solid tumors with FGFR1 or FGFR2 amplification or FGFR3 mutation, for which no further effective standard anticancer treatment existsXx_NEWLINE_xXPatients must have histologically or cytologically confirmed diagnosis of malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or for whom CPT-11 treatment would be a viable therapy regimen; patients with solid hematologic malignancies (Hodgkin’s and non-Hodgkin’s lymphomas) may be included as long as a bone marrow has been performed within 6 weeks of treatmentXx_NEWLINE_xXPatients enrolled on the dose escalation for intermittent ABT-888 portion of the study must histologically or cytologically confirmed diagnosis of malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or for whom CPT-11 treatment would be a viable therapy regimen; patients with solid hematologic malignancies (Hodgkin’s and non-Hodgkin’s lymphomas) may be included as long as a bone marrow has been performed within 6 weeks of treatmentXx_NEWLINE_xXPatients must have histologically or cytologically confirmed metastatic, high grade NET (Ki67 > 20%), excluding any high grade NETs of large or small cell type of lung/thymus origin and Merkel cell carcinomaXx_NEWLINE_xXHistologically or cytologically confirmed extensive-stage small-cell lung cancer (SCLC).Xx_NEWLINE_xXHistologically confirmed diagnosis of advanced or metastatic clear cell or papillary renal cell carcinoma or histologically confirmed clear cell ovarian carcinoma.Xx_NEWLINE_xXHistologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group [VALG] staging system)Xx_NEWLINE_xXHistologically or cytologically confirmed RCC with a clear cell component (subjects with pure papillary cell tumor or other non-clear cell histologies, including collecting duct, medullary, chromophobe, and unclassified RCC are excluded).Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of advanced non-small cell lung cancer (stage IIIB or IV) or recurrent disease. Subjects with known EGFR mutations or ALK or ROS1 gene rearrangements must have also failed prior EGFR or ALK or ROS1 tyrosine kinase inhibitor, respectively (PD or unacceptable toxicity). Subjects may have received PD-1 or PDL-1 inhibitors. There is no limit on lines of prior anti-cancer therapy.Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of pancreatic cancer.Xx_NEWLINE_xXHistologically or cytologically confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including patients with SCCHN of unknown primary or non-squamous histologies (eg, nasopharynx or salivary gland)Xx_NEWLINE_xXHistologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, not amenable for salvage surgery or radiotherapy.Xx_NEWLINE_xXA histologically or cytologically confirmed solid tumor that is metastatic, unresectable, or recurrent and for which standard therapies do not exist or are no longer effective a. Patients must not be considered eligible for a potentially curative resectionXx_NEWLINE_xXPatient must have histologically or cytologically confirmed well differentiated or moderately differentiated (low grade or intermediate grade) neuroendocrine tumor that is locally advanced or metastatic and not of pancreatic originXx_NEWLINE_xXHistologically confirmed diagnosis of DLBCLXx_NEWLINE_xXHistologically or cytologically confirmed advanced fibrolamellar carcinoma (FLC).Xx_NEWLINE_xXHistologically or cytologically documented diagnosis of NSCLCXx_NEWLINE_xXPatients must have histologically or cytologically confirmed diagnosis (from primary lesion and/or lymph nodes) of Squamous Cell Cancer of the oropharynx, hypopharynx or larynx (For patients with oropharynx primary, the tumor must be negative for p16 by immunohistochemistry).Xx_NEWLINE_xXMen and women, 18 years or older, with histologically or cytologically-confirmed, advanced solid tumors, Non-Hodgkin Lymphona (NHL), Multiple Myloma (MM), or advanced unresectable solid tumors limited to the tumor types below.Xx_NEWLINE_xXPatients with histologically confirmed metastatic colorectal cancer, who have received and/or progressed on a prior oxaliplatin-based chemotherapy regimenXx_NEWLINE_xXHistologically-confirmed diagnosis of urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra, that is transitional cell, or mixed transitional/non-transitional (predominantly transitional) cell type.Xx_NEWLINE_xXHistologically or cytologically-confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra.Xx_NEWLINE_xXFor Phase 1, subjects with histologically or cytologically confirmed advanced or metastatic solid tumors that have failed prior standard therapy (disease progression; subject intolerance is also allowable).Xx_NEWLINE_xXInclusion Criteria:\n\n        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please\n        visit www.BMSStudyConnect.com\n\n          -  Patients with metastatic or advanced solid tumors\n\n          -  Women with histologically or cytologically confirmed triple negative breast carcinoma\n\n          -  Participants with histologically or cytologically confirmed pancreatic adenocarcinoma\n\n          -  Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer\n             (NSCLC)\n\n        Exclusion Criteria:\n\n          -  Active brain metastases or leptomeningeal metastases.\n\n          -  Any serious or uncontrolled medical disorder\n\n          -  Prior malignancy active within the previous 3 years\n\n        Other protocol defined inclusion/exclusion criteria could applyXx_NEWLINE_xXHistologically confirmed diagnosis of R/R AITL (eligibility needs to be confirmed by central pathological review).Xx_NEWLINE_xXPart A only: Histologically or cytologically confirmed metastatic and/or advanced solid tumors with documented progressive disease for whom no further standard therapy is indicated.Xx_NEWLINE_xXPart B only: 5. Histologically or cytologically confirmed, molecularly selected (i.e. BRAFV600 positive and/or PI3K mutation positive) advanced solid tumors. Prior molecular characterization should be based using a regulatory approved assay or analytically validated assay.Xx_NEWLINE_xXHistologically or cytologically confirmed Stage IIIB-IVB NSCLCXx_NEWLINE_xXHistologically confirmed renal cell carcinoma (RCC) with a clear-cell component.Xx_NEWLINE_xXPathologically confirmed MCL.Xx_NEWLINE_xXHave a histologically or cytologically confirmed diagnosis of non-resectable, recurrent, or metastatic biliary tract adenocarcinoma (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or Ampulla of Vater) .Xx_NEWLINE_xXFor Cohort 1: has histologically or cytologically confirmed diagnosis of HCC (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible) based on pathology reportXx_NEWLINE_xXCohort C: Histologically confirmed metastatic solid tumor of epithelial origin, including both NSCLC and non-NSCLC, with radiographic evidence by MRI of at least one measurable brain lesion as defined by RANO criteria that requires corticosteroids for symptomatic controlXx_NEWLINE_xXHistologically confirmed diagnosis of FL or MCL according to WHO 2008Xx_NEWLINE_xXHistologically confirmed unresectable advanced or recurrent esophageal cancerXx_NEWLINE_xXSmall-cell lung cancer (SCLC) defined as a histologically confirmed diagnosis of SCLC and must have received at least 1 chemotherapy-containing regimen for advanced disease (recurrent or metastatic).Xx_NEWLINE_xXA histologically or cytologically confirmed cancer that is metastatic, unresectable, or recurrent and for which treatment with ipilimumab, or nivolumab, or pembrolizumab is a reasonable therapeutic option in the opinion of the investigator.Xx_NEWLINE_xXSubjects must have a histologically or cytologically confirmed advanced or metastatic tumor for which no effective standard therapy is available.Xx_NEWLINE_xXHave histologically or cytologically confirmed squamous NSCLC.Xx_NEWLINE_xXDiagnosis of histologically or cytologically confirmed, advanced solid tumor malignancy that is refractory to or not a candidate for standard therapyXx_NEWLINE_xXHistologically or cytologically confirmed, treatment-naïve Stage IV squamous NSCLCXx_NEWLINE_xXHave confirmed diagnosis of MPM with the following characteristics:Xx_NEWLINE_xXHistologically or cytologically confirmed urothelial carcinoma of the bladder or mixed histology bladder cancerXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of unresectable or metastatic malignant melanoma, including cutaneous, ocular, mucosal and unknown primary tumour.Xx_NEWLINE_xXPatients must have pathologically confirmed GISTXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of NSCLC with single activating EGFR mutations (L858R or Exon19Del).Xx_NEWLINE_xXHistologically or cytologically confirmed non-small cell lung cancer; patients with a suspected lung cancer are eligible, but pathology must be confirmed prior to initiating treatment on study; neuroendocrine carcinomas are not eligible; carcinomas with neuroendocrine differentiation are eligibleXx_NEWLINE_xXHistologically or cytologically confirmed metastatic breast cancer relapsed or refractory to approved standard available treatmentXx_NEWLINE_xXMalignant pleural mesothelioma (histologically confirmed epithelial)Xx_NEWLINE_xXHistologically- or cytologically-confirmed diagnosis of advanced/unresectable or metastatic MEL or RCC (Part 1A only) with predominantly clear cell elementsXx_NEWLINE_xXParticipants must have histologically confirmed B-cell NHLXx_NEWLINE_xXHistologically or cytologically confirmed carcinoma of the breastXx_NEWLINE_xXHas histologically or cytologically confirmed advanced, measurable or non-measurable metastatic solid tumors for which the patients have no available therapy to convey clinical benefit Expansion Phase only: The target population should include at leastXx_NEWLINE_xXHistologically confirmed diagnosis of melanomaXx_NEWLINE_xXHistologically- or cytologically-confirmed diagnosis of NSCLC that is anti-programmed cell death ligand 1 (PD-L1) positive per central laboratory reviewXx_NEWLINE_xXPatients must have histologically or cytologically confirmed evidence of pancreatic carcinomaXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of HCCXx_NEWLINE_xXHistologically confirmed diagnosis of malignant melanoma.Xx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis; confirmation may be obtained from any Clinical Laboratory Improvement Amendments (CLIA) certified laboratory (lab)Xx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis; confirmation may be obtained from any CLIA certified labXx_NEWLINE_xXPatient must have a histologically confirmed diagnosis of non-transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis including but not limited to squamous cell, neuroendocrine, adenocarcinoma including urachal and sarcomatoid; confirmation may be obtained from any CLIA certified labXx_NEWLINE_xXHistologically confirmed melanoma of cutaneous originXx_NEWLINE_xXHistologically documented diagnosis of proven glioblastoma (GBM)Xx_NEWLINE_xXPatients must be newly diagnosed with histologically-proven hepatoblastomaXx_NEWLINE_xXHistologically or cytologically confirmed invasive breast carcinoma with local recurrence or radiological evidence of metastatic disease.Xx_NEWLINE_xXHave histologically or cytologically confirmed SCLC (undifferentiated small-cell carcinoma arising in or consistent with lung cancer origin).Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of selected advanced or metastatic solid tumors.Xx_NEWLINE_xXHistologically and/or cytologically confirmed and radiographically measurable adenocarcinoma of the colon or rectum that is metastatic and/or unresectable; subjects must have been treated with a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan, and an anti-VEGF monoclonal antibody (bevacizumab, ramucirumab, or ziv-aflibercept), or have contraindication to such treatmentXx_NEWLINE_xXHistologically or cytologically confirmed extensive-stage disease small cell lung cancer (ED SCLC) with ongoing clinical benefit (stable disease [SD], partial response [PR], or complete response [CR]) following completion of 4 cycles of first-line platinum-based therapyXx_NEWLINE_xXHistologically or cytologically confirmed urothelial carcinoma (confirmed at the enrolling institution) of the bladder, ureter, urethra, or renal pelvis; patients with mixed histologies are required to have a predominant urothelial component as reviewed by the pathologist at the treating institutionXx_NEWLINE_xXMuscle invasive urothelial carcinoma of the bladder histologically confirmed at the enrolling institution; (urothelial carcinoma invading into the prostatic stroma with no histologic muscle invasion is allowed provided the extent of disease is confirmed via imaging and/or EUA)Xx_NEWLINE_xXHistologically documented diagnosis of DLBCL.Xx_NEWLINE_xXHistologically or cytologically proven metastatic breast cancer (metastases can be proven with imaging results in certain circumstances provided that the initial tumor was demonstrated histologically)Xx_NEWLINE_xXHistologically confirmed cervical cancer\r\n* Histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, stages IB2, IIA, IIB, IIIB, and IVA; stage IB1 with positive pelvic or para-aortic nodes based on magnetic resonance imaging (MRI) is also eligible\r\n* No evidence of distant metastases (based on PET/CT done within 4 weeks of start of treatment)\r\n* Recurrent cervical cancer is not eligibleXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of metastatic uveal melanoma (mUM)Xx_NEWLINE_xXHistologically or cytologically confirmed T 3/4 or N+ (> 1 cm in size or fludeoxyglucose F-18 [FDG] avid) gastric or gastroesophageal (GE) junction cancer; diagnosis must be confirmed a Dana-Farber (DF)/Harvard Cancer Center (HCC) institution pathology department prior to registrationXx_NEWLINE_xXPatients must have pathologically confirmed GISTXx_NEWLINE_xXHave histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC) (Stage IIIb or greater)Xx_NEWLINE_xXPatients must have histologically-confirmed endometrial carcinoma (endometrioid and mixed endometrioid tumors, any grade).Xx_NEWLINE_xXHistologically confirmed colorectal cancer that is either clinically or histologically proven to be metastatic and has progressed on regimens containing a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan, bevacizumab and an anti-EGFR antibody (if tumor is RAS wild-type), or where the treatment was not tolerated or contraindicatedXx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of Ph+ ALLXx_NEWLINE_xXPatients must have pathologically or cytologically confirmed adenoid cystic carcinoma; cancers arising from non-salivary gland primary sites are allowedXx_NEWLINE_xXHistologically or cytologically confirmed metastatic and/or unresectable progressive, well differentiated carcinoid or pancreatic neuroendocrine tumor (NET) carcinoidsXx_NEWLINE_xXHistologically or cytologically confirmed metastatic PDAC, no more than 1 prior chemotherapy regimen or treatment-naïve patientsXx_NEWLINE_xXHistologically confirmed, locally recurrent or metastatic clear cell renal cell carcinomaXx_NEWLINE_xXTumors must be histologically or cytologically proven and considered low or intermediate grade; patients with high grade neuroendocrine carcinomas or small cell carcinomas are excluded from the studyXx_NEWLINE_xXPostmenopausal women with histologically or cytologically confirmed invasive, ER+/HER- (defined by local guidelines) metastatic or inoperable, locally advance breast cancerXx_NEWLINE_xXPatients must have histologically confirmed diagnosis of unresectable malignant pleural mesotheliomaXx_NEWLINE_xXParticipant has histologically or cytologically confirmed squamous or non-squamous non-small cell lung cancer (NSCLC).Xx_NEWLINE_xXHistologically confirmed newly diagnosed glioblastoma; patients with an initial diagnosis of a lower-grade glioma are eligible if a subsequent biopsy was determined to be glioblastoma and they received no prior treatmentXx_NEWLINE_xXPatients must have histologically confirmed, untreated non-small cell lung cancer that are considered non-metastatic, unresectable for which chemoradiation is the definitive therapyXx_NEWLINE_xXMetastatic or recurrent merkel cell carcinoma (MCC) confirmed by histologyXx_NEWLINE_xXHistologically or cytologically confirmed advanced RCC with clear cell componentXx_NEWLINE_xXHistologically or cytologically confirmed small cell lung cancer (SCLC)Xx_NEWLINE_xXHistologically confirmed recurrent or metastatic NSCLC (adenocarcinoma, large cell, squamous cell, or not otherwise specified) that has either progressed during or after platinum-based chemotherapyXx_NEWLINE_xXThe participant has a histopathologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction (GEJ).Xx_NEWLINE_xXHistologically- or cytologically- confirmed CRCXx_NEWLINE_xXParticipants must have unresectable or metastatic histologically confirmed intrahepatic cholangiocarcinomaXx_NEWLINE_xXHistologically or cytologically confirmed low or intermediate grade, unresectable well differentiated foregut neuroendocrine tumors (thymic, bronchopulmonary, gastric, duodenal and pancreatic); patients with multiple neuroendocrine tumors associated with MEN1 syndrome will be eligibleXx_NEWLINE_xXPatients must have histologically or cytologically confirmed gastrointestinal (GI) malignancies or ovarian cancer prior to entering this studyXx_NEWLINE_xXHistologically or cytologically confirmed pleural or peritoneal malignant mesothelioma, epithelial, sarcomatoid, or biphasic subtypesXx_NEWLINE_xXPatient must have histologically or cytologically confirmed intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer or may undergo a repeat biopsy for histologic confirmation if pre-existing biopsy is not sufficient for diagnosisXx_NEWLINE_xXSubject has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive breast cancer by local laboratory (based on most recently analyzed biopsy).Xx_NEWLINE_xXHistologically confirmed diagnosis of indolent B-cell NHL, with histological subtype limited to the following:Xx_NEWLINE_xXHistologically confirmed diagnosis of FL grade 3b.Xx_NEWLINE_xXHistologically- or cytologically-confirmed recurrent or metastatic head and neck squamous cell carcinoma considered incurable by local therapiesXx_NEWLINE_xXHistologically confirmed diagnosis of advanced (metastatic, recurrent, or unresectable) cancer with mutations in any of the following genes: TSC1, TSC2, NF1, NF2, or STK11Xx_NEWLINE_xXHistologically confirmed glioblastomaXx_NEWLINE_xXHistologically- or cytologically-confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra (transitional cell and mixed transitional/non-transitional cell histologies)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed stage IV non-small cell lung cancer, or recurrent non-small cell lung cancer which is not amenable to curative intent therapyXx_NEWLINE_xXHistologically confirmed squamous cell carcinoma of any other primary anatomic location in the head and neck;Xx_NEWLINE_xXPatients must have histologically confirmed gastrointestinal malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective, or for whom FOLFOX would be an appropriate therapyXx_NEWLINE_xXPatients must have histologically or cytologically confirmed previously treated metastatic squamous cell carcinoma of the anal canalXx_NEWLINE_xXPatients must have histologically proven metastatic non-small cell lung cancer (stage IV disease or recurrent metastatic disease, according to the 7th edition of the lung cancer tumor, nodes, metastasis [TNM] classification system) (for cohort A), or histologically proven metastatic small cell lung cancer (extensive stage or recurrent metastatic disease) for cohort B; (patients with tumors having mixed small cell and non-small cell elements may be enrolled on cohort B), or females with histologically or cytologically confirmed carcinoma of the breast (either the primary or metastatic lesions) for whom single-agent cytotoxic chemotherapy is indicatedXx_NEWLINE_xXHistory of histologically-confirmed bilateral breast cancerXx_NEWLINE_xXMetastatic histologically or cytologically confirmed uveal melanoma with pathologic confirmation at a participating center that is judged to be progressive in the opinion of the treating physician; for the dose escalation portion of the trial only, patients with non-uveal melanoma harboring a GNAQ or GNA11 mutation will also be eligibleXx_NEWLINE_xXSubject must have cytologically or histologically confirmed advanced or metastatic non-squamous NSCLC and are current or former smokers.Xx_NEWLINE_xXHistologically- or cytologically-confirmed diagnosis of urothelial cancer of the renal pelvis, ureter, bladder, or urethra, that is transitional cell or mixed transitional/non-transitional (predominantly transitional) cell typeXx_NEWLINE_xXHistologically- or cytologically-confirmed recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapiesXx_NEWLINE_xXHas histologically- or cytologically-confirmed recurrent disease not amenable to curative treatment with local or systemic therapy, or metastatic (disseminated) head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapiesXx_NEWLINE_xXHistologically or cytologically confirmed invasive breast cancer with distant metastasisXx_NEWLINE_xXHistologically confirmed recurrent or metastatic SCCHNXx_NEWLINE_xXHistologically confirmed squamous cell carcinoma of any other primary anatomic location in the head and neckXx_NEWLINE_xXPatients must have histologically confirmed predominantly urothelial carcinoma of the bladder, ureter, or urethraXx_NEWLINE_xXHistologically or cytologically proven diagnosis of non-small cell lung cancerXx_NEWLINE_xXSubjects with histologically or cytologically documented NSCLC.Xx_NEWLINE_xXPatients with histologically or cytologically confirmed solid malignancy are eligible for treatment as long as insurance approval for docetaxel is obtainedXx_NEWLINE_xXPatients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary, follicular, or poorly differentiated subtypes and their respective variants)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed adenocarcinoma of esophagus or gastroesophageal junction, or stomach which is Gli-1 positive (labeling index [LI] greater than or equal to 5%); testing is to be performed in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory; the patients must have an archival tumor sample to facilitate this testingXx_NEWLINE_xXHistologically or cytologically confirmed advanced RCC with predominantly clear-cell subtype with primary tumor resectedXx_NEWLINE_xXHistologically or cytologically confirmed carcinoma of the prostateXx_NEWLINE_xXSubject must have cytologically or histologically confirmed squamous NSCLC.Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of pancreatic carcinoma (dose escalation and MTD expansion components).Xx_NEWLINE_xXPatients must have pathologically or cytologically confirmed adenoid cystic carcinoma; cancers arising from non-salivary gland primary sites are allowedXx_NEWLINE_xXHave histologically or cytologically confirmed locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) that is anaplastic lymphoma kinase (ALK+).Xx_NEWLINE_xXHistologically or cytologically-confirmed metastatic renal cell carcinoma of clear cell histology; prior nephrectomy is not a requirement for eligibilityXx_NEWLINE_xXPHASE I: Participants must have histologically confirmed breast cancer that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed MCC that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effectiveXx_NEWLINE_xXA histologically confirmed solid tumor of the gastrointestinal tract includingXx_NEWLINE_xXParticipants must have histologically confirmed malignancy with a RAS mutation (via any Clinical Laboratory Improvement Amendments [CLIA]-certified method) that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXSubjects with histologically confirmed Grade IV malignant gliomaXx_NEWLINE_xXHistologically or cytologically confirmed GIST by the Laboratory of Pathology, National Cancer Institute (NCI)Xx_NEWLINE_xXHistologically or cytologically confirmed non-muscle invasive bladder cancer [Ta, T1 or Tis (CIS)] that has been removed by transurethral resectionXx_NEWLINE_xXPatients with unresectable or metastatic histologically confirmed sporadic or NF1 associated high grade MPNSTXx_NEWLINE_xXHistologically confirmed malignant pleural mesothelioma that is not metastatic or unresectableXx_NEWLINE_xXHistologically or cytologically confirmed breast cancer with evidence of metastatic disease.Xx_NEWLINE_xXHistologically or cytologically documented squamous cell carcinoma of the oropharynx, larynx or hypopharynx; human papillomavirus (HPV) status will not be assessed for eligibilityXx_NEWLINE_xXHistologically or cytologically proven diagnosis of prostate cancer.Xx_NEWLINE_xXParticipants must have histologically or cytologically confirmed cervical cancer which is now recurrent or metastatic and is refractory to curative therapy or established treatments; histologic or cytologic confirmation of the original primary tumor is required; all histologic types of cervical origin are permittedXx_NEWLINE_xXPathologically or cytologically confirmed esophagogastric cancerXx_NEWLINE_xXHistologically confirmed squamous cell carcinoma of the cervix (any grade) or histologically confirmed grade 1 or 2 adenocarcinoma of cervixXx_NEWLINE_xXHistologically or cytologically confirmed malignant pleural or peritoneal mesothelioma (MPM)Xx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of epithelioid, sarcomatoid, or mixed-type malignant pleural or peritoneal mesothelioma that is not amenable to surgeryXx_NEWLINE_xXHistologically confirmed AML with >20% blastsXx_NEWLINE_xXHistologically or cytologically confirmed diagnosisXx_NEWLINE_xXHistologically confirmed intrahepatic cholangiocarcinoma (also variously reported as peripheral cholangiocarcinoma, cholangiolar carcinoma or cholangiocellular carcinoma) (ICC); confirmation of the diagnosis must be made at MSKCC or at the participating institution prior to initiating protocol therapyXx_NEWLINE_xXHistologically or cytologically proven SCLC that has relapsed or been refractory after at least one line of chemotherapyXx_NEWLINE_xXSuspected or histologically/cytologically confirmed head and neck squamous cell carcinoma (HNSCC) of the oral cavity, stage III, IVA or IVB (according to the American Joint Committee on Cancer [AJCC] 7th edition); patients with a suspected lesion may be enrolled and a baseline biopsy will be obtained as part of the study; if squamous cell histology is not confirmed, patients will be discontinued from the studyXx_NEWLINE_xXEligibility for dose escalation cohort: histologically or cytologically confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXEligibility for the expansion cohort: Histologically or cytologically confirmed colon or rectal adenocarcinoma for which curative treatment does not exist; patients must have documented progression or intolerance to at least one prior regimen containing 5-fluorouracil or capecitabine and oxaliplatinXx_NEWLINE_xXPatients must have newly diagnosed, histologically or cytologically confirmed squamous cell carcinoma or undifferentiated carcinoma of the oropharynx; patients must have been determined to have resectable oropharyngeal disease; patients with primary tumor or nodal metastasis fixed to the carotid artery, skull base or cervical spine are not eligibleXx_NEWLINE_xXPatients must have a histologically or cytologically confirmed non-central nervous system (CNS) primary solid malignancy at the time of initial diagnosis; NOTE: brain lesions are not required to have pathologic confirmation; in addition, a copy of the pathology report for the primary tumor is sufficient for registration purposesXx_NEWLINE_xXHistologically-confirmed non-germinal center B-cell subtype DLBCLXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed stage IV or recurrent non-small cell lung cancer with a documented exon 20 insertion mutation in EGFR (exon 20 insertion/deletion and deletion mutations will also be allowed)Xx_NEWLINE_xXDiagnosis of hepatocellular carcinoma (HCC) confirmed histologically, excluding mixed HCC histology (e.g. HCC plus cholangiocarcinoma) or fibrolamellar variantXx_NEWLINE_xXHistologically or cytologically confirmed squamous cell carcinoma of the head and neckXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed advanced (stage IV or recurrent) non-small cell lung cancerXx_NEWLINE_xXPatients must have histologically or cytologically confirmed advanced or metastatic cancer for which capecitabine treatment is considered a standard treatment optionXx_NEWLINE_xXPatient has a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive as assessed by the FDA approved Abbott FISH Test.Xx_NEWLINE_xXPatient must have histologically or pathologically confirmed locally unresectable or metastatic low or intermediate grade pancreatic neuroendocrine tumor, excluding small cell carcinomaXx_NEWLINE_xXHistologically or cytologically documented NSCLCXx_NEWLINE_xXHistologically/cytologically confirmed diagnosis of squamous cell carcinoma of head and neck origin not amenable to curative intent therapy; both human papillomavirus (HPV)(+) and HPV(-) tumors are eligible; tumors (squamous histology) of unknown primary that are clearly of squamous histology and likely related to the head and neck area are eligibleXx_NEWLINE_xXPatients must have histologically-confirmed advanced or recurrent endometrial carcinoma (endometrioid and mixed tumors, any grade) that is refractory to curative therapy or established treatmentsXx_NEWLINE_xXParticipants must have histologically confirmed prostate cancer.Xx_NEWLINE_xXPatients must have histologically confirmed malignancy that is metastatic or unresectableXx_NEWLINE_xXA histologically or cytologically confirmed solid tumor that is metastatic, unresectable, or recurrent and for which standard curative or palliative therapies do not exist or are no longer effective.Xx_NEWLINE_xXA histologically or cytologically confirmed colorectal cancer that is metastatic, unresectable, or recurrent.Xx_NEWLINE_xXHistologically confirmed advanced HCCXx_NEWLINE_xXHistologically or cytologically confirmed metastatic or recurrent NSCLC; primary or metastatic site may be used for histologyXx_NEWLINE_xXHistologically or cytologically confirmed, locally advanced, inoperable, or metastatic solid tumors. Subjects eligible for enrollment in the Expanded Cohort must have documented and/or confirmed FGFR genetic alterations, including iCCA with FGFR2 gene fusion.Xx_NEWLINE_xXPatients must have newly diagnosed (i.e., within 5 weeks), histologically or cytologically confirmed glioblastoma multiformeXx_NEWLINE_xXHistologically or cytologically proven prostate carcinomaXx_NEWLINE_xXPatients must have histologically confirmed solid malignancy that is metastatic or unresectable or lymphoma, for which standard curative or palliative measures that improve survival by at least three months do not exist or are no longer effective; for the purpose of this study patients with leukemia are not eligibleXx_NEWLINE_xXHistologically confirmed diagnosis of mycosis fungoides (MF) or Sezary Syndrome (SS)Xx_NEWLINE_xXHistologically confirmed AL or LCDD (from any time prior to screening)Xx_NEWLINE_xXHistologically confirmed V600E or V600K BRAF mutant melanomaXx_NEWLINE_xXPatient must have histologically or cytologically confirmed diagnosis of incurable metastatic or recurrent head and neck squamous cell carcinomaXx_NEWLINE_xXDiagnosis of non-small cell lung cancer (NSCLC), histologically or cytologically confirmedXx_NEWLINE_xXHistologically confirmed, previously untreated invasive head and neck squamous cell carcinoma OR histologically confirmed not yet treated recurrent head and neck squamous cell carcinoma (must be at least 3 months after diagnosis and completion of treatment for primary disease or last recurrence); patients may have local stage I or II, or locoregionally advanced HNSCC stage III or IV of the oral cavity, oropharynx, larynx, hypopharynx, or unknown primary, but no metastatic disease; intent to treat with primary radiotherapy +/- chemotherapyXx_NEWLINE_xXIn the dose-expansion phase: histologically- or cytologically- confirmed advanced solid tumor where if an approved first-line therapy is available, subjects must have failed, be intolerant to, be ineligible for, or have refusedXx_NEWLINE_xXPatient must have histologically confirmed p16 positive squamous cell carcinoma of the oropharynx (OPSCC)Xx_NEWLINE_xXhistologically-confirmed diagnosis according to REAL/WHO classification, of the following B-cell lymphomas :Xx_NEWLINE_xXPatient must have a histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective (dose-escalation cohorts only)Xx_NEWLINE_xXPatient must have a histologically or cytologically confirmed diagnosis of pancreatic cancer or poorly differentiated neuroendocrine tumor and must have been treated with a regimen with known benefit for pancreatic cancer/poorly differentiated neuroendocrine tumor (MTD expansion cohort only)Xx_NEWLINE_xXHistologically-  or cytologically-confirmed, treatment naive (or status post treatment regimens of tyrosine kinase inhibitor and/or immunotherapy) stage IV non-squamous, NSCLCXx_NEWLINE_xXPatients must have histologically or cytologically confirmed renal cell carcinoma except medullary or collecting duct subtypes; sarcomatoid differentiation will be allowedXx_NEWLINE_xXHistologically confirmed diagnosis of indolent B-cell NHL, with histological subtype limited to the following:Xx_NEWLINE_xXHistologically or cytologically confirmed non-small cell lung cancer; mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible; cytologic or histologic elements can be established on metastatic tumor aspirate or biopsy; sputum cytology alone is not sufficientXx_NEWLINE_xXPatients with histologically confirmed grade III or IV astrocytoma, oligoastrocytoma, and oligodendroglioma who are at first or second recurrenceXx_NEWLINE_xXPre- and post-menopausal women newly diagnosed with DCIS histologically confirmed on breast core biopsyXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of sarcoma of soft tissue; (patients with liposarcoma, bone sarcoma or gastrointestinal stromal tumor [GIST] will be excluded)Xx_NEWLINE_xXMuscle invasive urothelial carcinoma of the bladder histologically confirmed at Memorial Sloan Kettering Cancer Center (MSKCC) or participating site; (urothelial carcinoma invading into the prostatic stroma with no histologic muscle invasion is allowed, provided the extent of disease is confirmed via imaging and/or endoscopic ultrasonic aspiration [EUA])Xx_NEWLINE_xXPatients must have metastatic histologically or cytologically confirmed uveal melanoma; (if histologic or cytologic confirmation of the primary is not available, confirmation of the primary diagnosis of uveal melanoma by the treating investigator can be clinically obtained, as per standard practice for uveal melanoma); pathologic confirmation of diagnosis will be performed at Columbia University, Memorial Sloan-Kettering Cancer Center (MSKCC) or Vanderbilt University Medical CenterXx_NEWLINE_xXHistologically confirmed CD30+ disease by central laboratory assessment and pathology reviewXx_NEWLINE_xXPhase Ia: Patients must have histologically or cytologically documented metastatic solid tumor malignanciesXx_NEWLINE_xXPhase Ib: Patients must have histologically or cytologically confirmed locally advanced renal cell carcinomaXx_NEWLINE_xXSubjects must have a histologically or cytologically confirmed metastatic or unresectable\r\n* Solid tumor (for phase I dose escalation portion), OR\r\n* virally mediated tumors (such as with HPV+ nasopharyngeal cancer, HPV+ cervical cancer) and liposarcoma (for expansion cohort)Xx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of endometrial cancer and no clinical evidence of extra-uterine disease on preoperative evaluationXx_NEWLINE_xXHistologically or cytologically confirmed breast cancer that is either locally recurrent or metastatic.Xx_NEWLINE_xXSubjects must have a histologically or cytologically confirmed solid tumor that is metastatic, unresectable or recurrent and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXHistologically confirmed diagnosis of melanomaXx_NEWLINE_xXPatients must have histologically confirmed relapsed/refractory Ewing's sarcoma or neuroblastomaXx_NEWLINE_xXLocally unresectable or metastatic, histologically-confirmed, carcinoid or pancreatic neuroendocrine tumor; tumors must be considered well- or moderately-differentiated; patients with poorly differentiated neuroendocrine carcinoma are excluded from the studyXx_NEWLINE_xXHistologically-confirmed MBC not deemed amenable to curative surgery or curative radiation therapyXx_NEWLINE_xXPatients with histologically confirmed supratentorial high-grade glioma will be eligible for this protocol.Xx_NEWLINE_xXSubjects must have histologically-confirmed chordomaXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed carcinoma; central pathology review is not required; however, pathology will be reviewed at Brigham and Women's Hospital (BWH)/Dana-Farber Cancer Institute (DFCI)Xx_NEWLINE_xXHistologically or cytologically documented advanced or metastatic solid tumors for which established therapy either does not exist or has proven ineffective or intolerableXx_NEWLINE_xXPatients’ biopsies must be histologically confirmed CD30 positive within 36 months of enrollmentXx_NEWLINE_xXPatients must have histologically or cytologically confirmed melanoma stage III/IV, unresectableXx_NEWLINE_xXHistologically confirmed, unresectable, metastatic diffuse gastric cancer including carcinoma of the gastro-esophageal junctionXx_NEWLINE_xXHave histologically confirmed carcinoma of the prostate that is metastatic or otherwise incurable, and a BMI defined as obese (i.e. > 30 kg/m^2); any histologic variant is acceptable other than small cell carcinomaXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of cancer (including epithelial carcinoma, sarcoma, and melanoma); the diagnosis can be done at Memorial Sloan-Kettering Cancer Center (MSKCC) or at participating institutionsXx_NEWLINE_xXNewly diagnosed, previously untreated patients with histologically or molecularly confirmed DSRCTXx_NEWLINE_xXPhase I: Participants must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective (or who are intolerant of such therapy)Xx_NEWLINE_xXhistologically or cytologically proven diagnosis of malignancy other than NSCLCXx_NEWLINE_xXCOHORT 1 ONLY: Patients must have pathologically or cytologically confirmed adenoid cystic carcinoma; cancers arising from non-salivary gland primary sites are allowedXx_NEWLINE_xXCOHORT 2 ONLY: Patients must have pathologically or cytologically confirmed salivary gland cancer of any histology except for adenoid cystic carcinomaXx_NEWLINE_xXPatients must have histologically or cytologically confirmed diagnosis of cancer not amenable to curative therapy.Xx_NEWLINE_xXHistologically confirmed Stage 4 or recurrent non-small cell lung cancerXx_NEWLINE_xXHistologically-confirmed HLXx_NEWLINE_xXHistologically confirmed metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) of the oral cavity, oropharynx, hypopharynx or larynx; metastatic or recurrent lesions of the nasopharynx and sinus are excludedXx_NEWLINE_xXPresumptive or histologically confirmed advanced or metastatic non-curable solid tumor (if limited to a single lesion, and may not be a candidate for curative surgery or radiation therapy).Xx_NEWLINE_xXHistologically or cytologically proven diagnosis of unresectable B3 thymoma or thymic carcinoma recurrent or progressing after prior chemotherapy (only one prior systemic therapy allowed)Xx_NEWLINE_xXFor anaplastic thyroid cancer (ATC), patients must have histologically or cytologically diagnosed advanced ATC.Xx_NEWLINE_xXDiagnosis Arm A: CLL (including SLL), DLBCL, or FL; SLL, DLBCL, and FL must be histologically confirmed Arm B: Histologically confirmed SLL or previous confirmation of B-cell CLL with a characteristic immunophenotype by flow cytometry Arm C: Histologically confirmed aggressive B-cell DLBCL, including FL transforming to DLBCL, transformed indolent lymphoma, MCL, or Grade 3b FL, according to the World Health Organization (WHO)/American Joint Committee on Cancer (AJCC) criteria Arm D: Histologically confirmed anti-CD20-refractory (defined as any subject with less than a PR to any prior anti-CD20-based therapy or progression within 6 months after completing therapy with any anti-CD20-based regimen, including maintenance rituximab) aggressive B-cell DLBCL, including FL transforming to DLBCL, transformed indolent lymphoma, MCL, or Grade 3b FL, according to the WHO/AJCC criteriaXx_NEWLINE_xXHistologically confirmed B-cell NHL (FL or DLBCL): Relapsed from or refractory to ? 1 prior regimen containing rituximab, either alone or in combination, and not be a candidate for hematopoietic SCT or BM transplantXx_NEWLINE_xXHistologically confirmed diagnosis of prostate cancerXx_NEWLINE_xXPatients must have histologically confirmed alveolar soft part sarcoma; pathology should be confirmed at the Laboratory of Pathology, National Institutes of HealthXx_NEWLINE_xXHistologically confirmed diagnosis of 1 of the following:\r\n* Anaplastic oligodendroglioma\r\n* Anaplastic oligoastrocytoma\r\n* Anaplastic astrocytomaXx_NEWLINE_xXPatients must have cytologically or histologically proven recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) from the primary tumor or lymph nodes of the oral cavity, larynx, oropharynx, or hypopharynx.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed urothelial tract carcinomaXx_NEWLINE_xXConfirmed diagnosis of AL amyloidosisXx_NEWLINE_xXHistologically or cytologically confirmed NSCLCXx_NEWLINE_xXHistologically or cytologically confirmed urothelial carcinoma.Xx_NEWLINE_xXUnresectable stage lll or IV, histologically confirmed diagnosis of one of the following solid tumors:Xx_NEWLINE_xXDose escalation phase: patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; OR safety dose expansion phase: patients must have histologically or cytologically confirmed relapsed or refractory small cell lung cancerXx_NEWLINE_xXPatients must have histologically or cytologically confirmed invasive cancer of the breastXx_NEWLINE_xXHistologically or cytologically confirmed stage IIIB or IV NSCLC with non-squamous histologyXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of small cell lung carcinoma. Subjects must have measurable disease per RECIST 1.1 (for Part 2 only).Xx_NEWLINE_xXHistologically confirmed diagnosis of B-cell iNHL, with histological subtype limited to the following:Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of metastatic colorectal cancer with a product related mutation in Ras (G12V, G12C, G12D, G12R, Q61L, Q61R, Q61H)Xx_NEWLINE_xXHistologically confirmed squamous cell carcinoma of the head and neck (SCCHN), from any of the following primary sites only: oral cavity, oropharynx, hypopharynx, and larynx.Xx_NEWLINE_xXHistologically or cytologically confirmed squamous or non-squamous NSCLCXx_NEWLINE_xXPatients must have a histologically or cytologically confirmed metastatic solid tumor malignancy for the phase I component; the phase II component will require patients to have histologically or cytologically confirmed non-small cell lung carcinoma regardless of histologyXx_NEWLINE_xXMust have histologically or cytologically confirmed non-squamous NSCLC.Xx_NEWLINE_xXPatients with histologically proven, unresectable, evaluable metastatic colorectal cancer, by RECIST criteriaXx_NEWLINE_xXHistologically confirmed colon or rectal cancer with metastatic diseaseXx_NEWLINE_xXHistologically confirmed diagnosis of classical HLXx_NEWLINE_xXHistologically confirmed MCLXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of CRCXx_NEWLINE_xXHistologically proven small cell lung cancer with progressive parenchymal brain involvement confirmed by imagingXx_NEWLINE_xXHas a histologically and/or cytologically confirmed diagnosis of NSCLC (squamous or nonsquamous).Xx_NEWLINE_xXHistologically confirmed diagnosis of predominant clear cell renal cell carcinoma.Xx_NEWLINE_xXSubjects with advanced, histologically or cytologically confirmed solid tumors described to express fibroblast growth factor receptor 2 (FGFR2) that are refractory to any standard therapyXx_NEWLINE_xXFor maximum tolerated dose (MTD) Dose Expansion: Subjects with advanced, histologically or cytologically confirmed triple-negative breast cancer who had undergone within 4 lines of systemic anti-cancer treatment and not eligible for standard therapy anymore.Xx_NEWLINE_xXHistologically confirmed diagnosis of B-lineage ALL. Verification of CD22 expression is not requiredXx_NEWLINE_xXHistologically confirmed metastatic and/or advanced malignant mesothelin-positive solid tumors as determined by central pathology lab reviewXx_NEWLINE_xXHistologically confirmed metastatic and/or advanced mesothelin-positive PDA as determined by central pathology lab reviewXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of NSCLC that is Stage IIIb, IV, or recurrent.Xx_NEWLINE_xXHistologically proven supratentorial GBM or gliosarcomaXx_NEWLINE_xXMust have histologically confirmed DLBCL that is relapsed or refractory to previous therapy.Xx_NEWLINE_xXHistologically confirmed DLBCL(Cohort C)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed SCCHN that is recurrent and/or metastatic and not amendable to curative therapy by surgery or radiation; SCCHN originating from the following sites are eligible: oral cavity, oropharynx, larynx, hypopharynx and paranasal sinus; for patients with a diagnosis of SCCHN of unknown origin, their eligibility must be reviewed and approved by the principal investigatorXx_NEWLINE_xXHistologically or cytologically confirmed B-cell NHL that has relapsed from, or is refractory to, standard therapies (including autologous transplantation) known to provide clinical benefit, but have not been treated with bendamustine for their lymphoma\r\n* Patients with limited exposure to Bendamustine (less than 2 full cycles) may be included, based on Principal Investigator (PI) discretionXx_NEWLINE_xXHistologically or cytologically confirmed (extensive-stage disease) ED SCLC (small cell lung cancer)Xx_NEWLINE_xXStage IV, histologically or cytologically confirmed NSCLC; confirmation may be obtained with the first protocol-specified tumor biopsyXx_NEWLINE_xXParticipants must have known HIV infection and histologically confirmed non-small cell lung cancer that is metastatic or unresectable; patients will be eligible regardless of tumor EGFR mutation statusXx_NEWLINE_xXMust have cytologically or histologically confirmed NSCLC with either:Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed cancerXx_NEWLINE_xXHistologically confirmed CD20 positive primary B-cell CNS lymphoma (PCNSL) confirmed by one of the following:Xx_NEWLINE_xXPatients must have a histologically or cytologically confirmed adenocarcinoma of the colon or rectum that is metastatic to the liver and unresectable and for which standard curative measures do not exist or are no longer effectiveXx_NEWLINE_xXHistologically confirmed recurrent squamous cell carcinoma of the oral cavity, pharynx, (oropharynx, larynx) and neckXx_NEWLINE_xXHistologically proven GBMXx_NEWLINE_xXPatients must have a histologically-confirmed primary diagnosis of high-grade glioma (HGG) (such as glioblastoma multiforme, gliosarcoma, anaplastic oligodendroglioma, anaplastic ganglioglioma, high grade astrocytoma, not otherwise specified [NOS]) that is recurrent or refractory to conventional therapy; patients with metastatic disease are not eligible; if there is evidence of the tumor arising from the ventricular system, patient is NOT eligibleXx_NEWLINE_xXSubjects with a histologically or cytologically confirmed diagnosis of solid tumors, advanced or metastatic, refractory to or relapsed from standard therapies or for which there is no known effective treatmentXx_NEWLINE_xXHistologically confirmed carcinoma of the kidney (clear-cell predominance)Xx_NEWLINE_xXPatients must be males with histologically confirmed and clinically localized low-grade and low-volume prostate cancer demonstrated at the time of initial diagnosisXx_NEWLINE_xXPatients in Parts 2 and 3 must have histologically confirmed diagnosis of CD30-positive DLBCLXx_NEWLINE_xXHistologically confirmed muscle invasive transitional cell carcinoma of the bladder at Memorial Sloan-Kettering Cancer Center (MSKCC); (Note: urothelial carcinoma invading into the prostatic stroma with no histologic muscle invasion is allowed, provided the extent of disease is confirmed via imaging and/or exam under anesthesia [EUA])Xx_NEWLINE_xXHistologically or cytology proven pancreatic ductal carcinomaXx_NEWLINE_xXHistologically confirmed solid tumors, including primary brain tumors; in subjects with brain stem or optic gliomas the requirement for histological confirmation may be waivedXx_NEWLINE_xXPatient has histologically/cytologically-confirmed HNSCC.Xx_NEWLINE_xXPatients with histologically confirmed viral related hepatocellular, SCLC, non-cutaneous/ non-uveal melanoma, ovarian, TNBC, Sarcoma, Bladder and RCC.Xx_NEWLINE_xXHistologically or cytologically confirmed, newly diagnosed non-squamous NSCLCXx_NEWLINE_xXHistologically confirmed colorectal cancer with at least one measurable metastatic lesion by RECIST v 1.1, that is considered unresectable at baselineXx_NEWLINE_xXHistologically confirmed diagnosis of osteosarcoma with lung metastasis, who have progressed on the prior line of therapy, or relapsedXx_NEWLINE_xXHistologically confirmed colorectal cancerXx_NEWLINE_xXHistologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective OR\r\n* Histologically or cytologically confirmed solid tumor for which single agent capecitabine is an appropriate treatment optionXx_NEWLINE_xXPatients with histologically/cytologically-confirmed HNSCCXx_NEWLINE_xXPatients must have histologically or cytologically confirmed non-squamous cell, non small cell carcinoma of the lungXx_NEWLINE_xXHistologically confirmed glioblastoma multiforme or gliosarcomaXx_NEWLINE_xXHistologically or cytologically confirmed invasive breast carcinoma at local institutionXx_NEWLINE_xXMESOTHELIOMA COHORTS (COHORTS 1 AND 2 ONLY): Subjects must have histologically confirmed epithelial or biphasic mesothelioma not amenable to potentially curative surgical resection; however, patients with biphasic tumors that have a >= 50% sarcomatoid component will be excluded; the diagnosis will be confirmed by the Laboratory of Pathology/Center for Cancer Research (CCR)/National Cancer Institute (NCI)Xx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis; confirmation may be obtained from any Clinical Laboratory Improvement Amendments (CLIA) certified lab orXx_NEWLINE_xXPatient must have a histologically confirmed diagnosis of non-transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis including but not limited to squamous cell, neuroendocrine, adenocarcinoma including urachal and sarcomatoid; confirmation may be obtained from any CLIA certified labXx_NEWLINE_xXHistologically or cytologically confirmed loco-regionally advanced head and neck squamous cell carcinoma (HNSCC), stage III to IVbXx_NEWLINE_xXHistologically or cytologically confirmed prostate cancerXx_NEWLINE_xXHistologically confirmed non-squamous histologies are not allowed; an exception is made for WHO type I-III nasopharynx histologiesXx_NEWLINE_xXHave a histologically confirmed diagnosis of predominant clear cell (conventional) Renal Cell Carcinoma (ccRCC).Xx_NEWLINE_xXFor Part 1a: Subjects with histologically or cytologically confirmed advanced or metastatic solid tumors that have failed prior standard therapy (including subject refusal or intolerance).Xx_NEWLINE_xXHave a histologically or cytologically confirmed diagnosis of stage IV NSCLC.Xx_NEWLINE_xXPHASE I: Patients must have metastatic/recurrent, histologically confirmed NSCLC that harbors an EGFR activating mutation (exon 21 L858R, exon 19 deletion, exon 18 G719X, exon 21 L861Q) with progressive disease by RECIST 1.1 on a previous EGFR-tyrosine kinase inhibitor (TKI); OR patients must have metastatic/recurrent histologically confirmed NSCLC that harbors an EGFR exon 20 insertion with progressive disease on platinum containing chemotherapyXx_NEWLINE_xXPHASE II COHORT B: Patients must have metastatic/recurrent histologically confirmed NSCLC that harbors an EGFR exon 20 insertion with progressive disease on or after platinum doublet chemotherapyXx_NEWLINE_xXHistologically confirmed squamous cell lung cancerXx_NEWLINE_xXHistologically proven squamous cell carcinoma of the head and neck with measurable disease that is either recurrent after attempted cure with surgery and/or radiation therapy or newly diagnosed disease with distant metastases or incurable at diagnosisXx_NEWLINE_xXPatients must have histologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXPatients must have histologically or cytologically confirmed stage IV or recurrent squamous cell lung cancer that harbors any of the NFE2L2 mutations; any KEAP1 mutation will be eligibleXx_NEWLINE_xXHistologically confirmed:Xx_NEWLINE_xXHistologically confirmed uterine leiomyosarcoma with disease limited to the uterus (determined by surgical staging or radiologic imaging).Xx_NEWLINE_xXPatients (except those with hepatocellular carcinoma) must have histologically or cytologically confirmed (at original diagnosis or subsequent recurrence or progression) solid tumor or lymphoma that is metastatic, unresectable, progressive, or recurrent, and for which standard curative or palliative measures do not exist or are no longer effective; patients with hepatocellular carcinoma do not require biopsy confirmation; a liver mass with raised alpha-fetoprotein level (>= 500 ng/mL), consistent radiographic changes, and serology and viral deoxyribonucleic acid (DNA)/ribonucleic acid (RNA) measurements consistent with chronic hepatitis will be sufficient to identify hepatocellular carcinoma without the need for pathologic confirmation of the diagnosis; patients with hepatocellular carcinoma must still, however, have disease that has failed standard therapy; having chronic hepatitis B or C will not exclude patients from participatingXx_NEWLINE_xXHistologically or cytologically confirmed disease;Xx_NEWLINE_xXFor the expansion cohort: women with histologically or cytologically confirmed TNBC (triple negative breast cancer)Xx_NEWLINE_xXPatient has a histologically and/or cytologically confirmed diagnosis of breast cancerXx_NEWLINE_xXConfirmed diagnosis of systemic AL amyloidosisXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of solid malignancy, for which no standard curative or life prolonging therapy is available.Xx_NEWLINE_xXTreatment Group A (TGA): Part 1 and Part 2: Any advanced solid tumor or lymphoma; Part 3: Histologically confirmed disease in specific solid tumors and lymphomasXx_NEWLINE_xXHistologically or cytologically confirmed Stage IV non-squamous NSCLCXx_NEWLINE_xXHistologically or cytologically documented, advanced, mixed non-small cell and small cell tumors or mixed adenosquamous carcinomasXx_NEWLINE_xXHistologically or cytologically confirmed solid tumor.Xx_NEWLINE_xXHistologically or cytologically confirmed advanced solid tumor with no available standard treatment options in the opinion of the investigator.Xx_NEWLINE_xXPatient with histologically/cytologically confirmed Primary Central Nervous System Lymphoma (PCNSL)Xx_NEWLINE_xXPart A Subjects with histologically or cytologically confirmed malignant advanced solid tumors, who have progressed on at least 1 prior chemotherapy, and for whom eitherXx_NEWLINE_xXHistologically or cytologically confirmed Stage IV squamous NSCLCXx_NEWLINE_xXHistologically or cytologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx) that is incurable by local therapy.Xx_NEWLINE_xXHistologically or cytologically documented advanced or metastatic solid tumors for which established therapy either does not exist or has proven ineffective or intolerableXx_NEWLINE_xXHistologically documented FL (Grade 1, 2 and 3A)Xx_NEWLINE_xXPatients with a histologically/cytologically confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors:Xx_NEWLINE_xXHistologically confirmed diagnosis of B-cell iNHL, with histological subtype limited to the following:Xx_NEWLINE_xXParticipants must have histologically or cytologically confirmed diagnosis of SCLCXx_NEWLINE_xXMetastatic, castrate resistant, histologically confirmed prostate cancer; surgically castrated or continuous medical castration for ? 8 weeks prior to screeningXx_NEWLINE_xXConfirmed diagnosis of refractory celiac disease Type 2 (RCD-II)Xx_NEWLINE_xXHistologically or cytologically confirmed primary, untreated SCCHN including variants. Patients must be candidates for surgical resection. Primary tumors of oral cavity, oropharynx, hypopharnyx or larynx are included.Xx_NEWLINE_xXSubject had histologically or cytologically confirmed diagnosis of advanced solid tumor (measurable or nonmeasurable disease) for which no standard therapy is available.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary, follicular, or poorly differentiated subtypes and their respective variants).Xx_NEWLINE_xXHistologically or cytologically proven squamous non-small cell lung cancer (NSCLC) where treatment with weekly paclitaxel is an appropriate treatment option.Xx_NEWLINE_xXHistologically or cytologically confirmed Stage IIIB or IV advanced or metastatic NSCLC with measurable neoplastic disease. Sputum cytology alone is not considered an acceptable method of diagnosis;Xx_NEWLINE_xXPatients with relapsed small cell lung cancer – diagnosis must be histologically confirmedXx_NEWLINE_xXHistologically confirmed GBMXx_NEWLINE_xXSubjects with a histologically or cytologically confirmed acute leukemia who are refractory to or have exhausted all available therapiesXx_NEWLINE_xXHistologically documented leiomyosarcomaXx_NEWLINE_xXHistologically or cytologically confirmed Stage IIIB or IV Non-Small Cell Lung Cancer.Xx_NEWLINE_xXHistologically or cytologically confirmed refractory colorectal cancerXx_NEWLINE_xXDiagnosis of NSCLC, histologically or cytologically confirmedXx_NEWLINE_xXHistologically confirmed non-small cell lung cancer (NSCLC), who are deemed to be surgical candidates by standard criteria; patients with all types of NSCLC (e.g., adenocarcinoma, squamous cell carcinoma) will be allowed to enrollXx_NEWLINE_xXHave histologically confirmed breast or ovarian carcinomaXx_NEWLINE_xXAutologous transplant eligible patients must have histologically or cytologically confirmed cluster of differentiation (CD)20 positive relapsed or refractory DLBCL by biopsy within 45 days prior to subject enrollment and must have been previously treated with an anthracycline and rituximab-containing regimenXx_NEWLINE_xXHistologically or cytologically confirmed metastatic and/or advanced solid tumors or lymphomas for which standard curative or life-prolonging treatment does not exist or is no longer effective or tolerable.Xx_NEWLINE_xXMust have histologically confirmed renal cell carcinoma of any pathologic subtype.Xx_NEWLINE_xXSubjects must have histologically or cytologically confirmed advanced solid tumor. However, Hepatocellular Carcinoma (HCC) subjects are allowed without histological confirmation as long as there is radiological diagnosis as per standard criteriaXx_NEWLINE_xXHistologically or cytologically confirmed mCRC not amenable to potentially curative resection with at least one measurable metastatic lesion, as defined by RECIST v1.1Xx_NEWLINE_xXHistologically confirmed HCCXx_NEWLINE_xXHistologically or cytologically confirmed advanced/metastatic SCLC or NSCLCXx_NEWLINE_xXPatients must have histologically or cytologically confirmed low or intermediate grade pancreatic NET; patients with neuroendocrine tumors associated with multiple endocrine neoplasia type 1 (MEN1) syndrome will be eligibleXx_NEWLINE_xXPrior diagnosis of HCC confirmed histologically.Xx_NEWLINE_xXSubjects with histologically or cytologically confirmed mCRC, Kirsten rat sarcoma wild-type (KRAS WT) at initial diagnosisXx_NEWLINE_xXHistologically documented hepatocellular carcinomaXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of solid tumor malignancy that is not responsive to standard therapies or for which there is no approved or curative therapy.Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of advanced or metastatic cutaneous melanoma that is determined to be BRAFV600 wild type and either NRAS wild type or NRAS mutation type. Note: Subjects with a melanoma of unknown primary origin may be allowed to enrol if all other types of melanoma (e.g., uveal, mucosal, or acral) can be reasonably ruled out.Xx_NEWLINE_xXHistologically confirmed cutaneous metastatic melanoma of V600 E, K, D or R.Xx_NEWLINE_xXHistologically or cytologically confirmed unresectable GBM. Subjects with recurrent disease whose prior pathology demonstrated GBM will not need to be re-biopsied. Subjects with prior low-grade glioma or anaplastic glioma are eligible if histological assessment demonstrates transformation into GBM.Xx_NEWLINE_xXHave a histologically or cytologically confirmed diagnosis of advanced solid tumor or lymphoma, or primitive hepatocarcinoma with radiological diagnosisXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of a solid tumor.Xx_NEWLINE_xXPatients must have metastatic histologically or cytologically confirmed uveal melanoma; if histologic or cytologic confirmation of the primary is not available, confirmation of the primary diagnosis of uveal melanoma by the treating investigator can be clinically obtained, as per standard practice for uveal melanoma; pathologic confirmation of metastatic disease will be performed at Memorial Sloan Kettering (MSK) or at a participating siteXx_NEWLINE_xXHistologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.Xx_NEWLINE_xXHistologically or cytologically confirmed stage IV non-small cell lung carcinoma (NSCLC), according to 7th Tumor/Node/Metastasis (TNM) classification (cytological specimens obtained by bronchial washing or brushing, or fine-needle aspiration are acceptable)Xx_NEWLINE_xXHistologically or cytologically confirmed unresectable NSCLCXx_NEWLINE_xXDose escalation phase: Subjects with histologically or cytologically confirmed advanced malignancies (solid tumors and malignant lymphomas) who were refractory to or had exhausted all available therapies. Subjects had to have evaluable or measurable disease (as per RECIST 1.1 or Cheson 2007 criteria).Xx_NEWLINE_xXExpansion phase only: Subjects with advanced, histologically or cytologically confirmed gastric cancer, triple negative breast cancer (TNBC), or diffuse large B-cell lymphoma (DLBCL), who were refractory to or had exhausted all available therapies. Subjects had to have evaluable or measurable disease (as per RECIST 1.1 or Cheson 2007 criteria).Xx_NEWLINE_xXHistologically or cytologically confirmed carcinoma of the bladder of all histologies except neuroendocrine differentiation or squamous cell histologyXx_NEWLINE_xXPatient has histologically confirmed diagnosis of GBM with documented recurrence after first line treatment including radiotherapy and TMZ (SoC), not suitable for curative surgery or re-irradiation.Xx_NEWLINE_xXHistologically confirmed R/M SCCHN of mucosal origin (e.g., oral cavity, oropharynx, hypopharynx, larynx) that is not amenable to further curative local therapy (e.g., surgery, radiation including re-irradiation) (1L R/M)Xx_NEWLINE_xXPatients must have histologically confirmed soft tissue or bone/cartilage sarcoma. Patients with sarcoma of small round blue cell tumor types are allowed. Gastrointestinal stromal tumors (GIST) are excluded.Xx_NEWLINE_xXHistologically confirmed diagnosis of PTCLXx_NEWLINE_xXPART II: Oncology participants must have histologically or cytologically diagnosed malignancy; ideally the subject has completed treatment within 6 months to a year and cancer is stableXx_NEWLINE_xXHistologically or cytologically confirmed invasive carcinoma of the breastXx_NEWLINE_xXHistologically confirmed esophageal squamous cell carcinoma (ESCC)Xx_NEWLINE_xXHistologically or cytologically documented breast cancerXx_NEWLINE_xXHistologically confirmed endometrial cancerXx_NEWLINE_xXHistologically confirmed HCC that is inoperable (where surgery is not indicated due to disease extension, co-morbidities, or other technical reasons), and not eligible for local therapyXx_NEWLINE_xXPatient must have histologically or cytologically confirmed refractory colorectal cancer (CRC)Xx_NEWLINE_xXDose determination cohorts: Histologically confirmed diagnosis of metastatic RCC of either clear cell or non-clear histology.Xx_NEWLINE_xXDose expansion cohorts: Histologically confirmed diagnosis of metastatic RCC of either clear cell or papillary histologyXx_NEWLINE_xXCytopathologically or histologically confirmed diagnosis of MMXx_NEWLINE_xXDOSE ESCALATION COHORT: subjects must have histologically or cytologically confirmed sarcoma that is metastatic or unresectableXx_NEWLINE_xXDOSE EXPANSION COHORT: subjects must have histologically or cytologically confirmed GIST that is metastatic or unresectableXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of a solid tumor for which no further effective standard treatment is available. Patients with lymphomas may be enrolled.Xx_NEWLINE_xXHistologically or cytologically confirmed melanomaXx_NEWLINE_xXHistologically or cytologically confirmed hepatocellular carcinoma that is metastatic, unresectable, or recurrent.Xx_NEWLINE_xXHistologically confirmed relapsed or refractory FL (Grades 1, 2, or 3a) or relapsed or refractory DLBCLXx_NEWLINE_xXHistologically or cytologically confirmed locally residual or recurrent cancer of the rectum or anusXx_NEWLINE_xXHistologically confirmed angiosarcomaXx_NEWLINE_xXHistologically confirmed non-small cell lung cancerXx_NEWLINE_xXNewly diagnosed, previously untreated patients with histologically or molecularly confirmed Ewing sarcomaXx_NEWLINE_xXHistologically confirmed intrahepatic cholangiocarcinoma (also variously reported as peripheral cholangiocarcinoma, cholangiolar carcinoma or cholangiocellular carcinoma) (ICC); confirmation of the diagnosis at the Memorial Sloan-Kettering Cancer Center (MSKCC) or at the enrolling institution must be obtained prior to initiation of protocol therapyXx_NEWLINE_xXMust have histologically proven glioblastomaXx_NEWLINE_xXPatients must have histologically or cytologically confirmed soft tissue sarcoma that is metastatic or unresectable and for which standard treatment that prolongs survival does not exist or is no longer effectiveXx_NEWLINE_xXPatients must have histologically confirmed metastatic alveolar soft part sarcoma that is not curable by surgery; diagnosis of malignancy must be confirmed by the department of pathology at the institution where the patient is enrolled prior to patient enrollmentXx_NEWLINE_xXPatients must have histologically confirmed solid malignancy (excluding lymphoma) that is metastatic or unresectable and for which standard curative or palliative systemic therapies (such as chemotherapy, targeted therapies or immunotherapy) do not exist or are no longer effectiveXx_NEWLINE_xXPart I: Patients with one of the following histologically- or cytologically-proven conditions: relapsed/refractory AML, relapsed/refractory MDS, or advanced CML in AP or BP (i.e., Acute Group patients).Xx_NEWLINE_xXHistologically- or cytologically-confirmed MPeM; epithelial, sarcomatoid, biphasic, multi-cystic, or well-differentiated papillary subtypes are allowedXx_NEWLINE_xXHistologically confirmed Stage III or IV recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)Xx_NEWLINE_xXFor Stage 2: Participants with histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (NSCLC); mixed histology that is predominantly squamous is acceptableXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) prior to fiducials placement and subsequent SBRT; because fiducials will be placed exclusively by ENB, which can also be used for pathological diagnosis of malignancy, there will be two categories of eligibility:\r\n* Participants already carry a histological or cytological diagnosis of NSCLC and will undergo an ENB procedure solely for the placement of fiducial tumor markers; participants in this category need not be newly diagnosed; a participant who was previously histologically or cytologically diagnosed with NSCLC and now presents with a new tumor confirmed by imaging may be treated on this protocol without an additional biopsy; in this case, the prior pathological diagnosis will be used to establish a NCLC diagnosis for this protocol\r\n* Participants present with an indeterminate lung tumor and undergo ENB for both NSCLC diagnosis and fiducials placement; in this setting, the subject will sign informed consent prior to the ENB procedure and be enrolled only after intraoperative histological or cytological confirmation of NSCLC and placement of fiducial markersXx_NEWLINE_xXPatient with histologically demonstrated, previously untreated glioblastomaXx_NEWLINE_xXHistologically or cytologically confirmed incurable Stage IIIb/IV NSCLC tumorXx_NEWLINE_xXHistologically confirmed aggressive B-cell DLBCL, including FL transforming to DLBCL & Grade III FLXx_NEWLINE_xXHistologically/cytologically confirmed, advanced solid tumors, AML or high risk and very high risk MDSXx_NEWLINE_xXHistologically or cytologically documented non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXPatients must have histologically documented or cytologically confirmed Hodgkin lymphoma with CD 30 expressionXx_NEWLINE_xXHistologically or cytologically confirmed non-squamous NSCLCXx_NEWLINE_xXHistologically or cytologically confirmed R/M HNSCC of the oral cavity, oropharynx, hypopharynx or larynx, not amenable for salvage surgery or radiotherapyXx_NEWLINE_xXHistologically confirmed diagnosis of conventional chondrosarcoma of any grade.Xx_NEWLINE_xXHistologically confirmed diagnosis of soft tissue sarcoma of high or intermediate grade with one of the following histological subtypes:Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of solid tumor in advanced stage which taxane-based therapy is a rational treatment option.Xx_NEWLINE_xXHistologically confirmed cancer with 1-4 brain metastases (except lymphoma or small cell histologies)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed metastatic uveal melanomaXx_NEWLINE_xXPatients aged ?18 years with a histologically or cytologically confirmed diagnosis of a solid tumor or lymphoma for which no further effective standard treatment is availableXx_NEWLINE_xXHistologically or cytologically confirmed invasive breast carcinomaXx_NEWLINE_xXConfirmed NSCLCXx_NEWLINE_xXHistologically/cytologically proven colorectal carcinomaXx_NEWLINE_xXhistologically or cytologically proven diagnosis of non-small cell lung cancerXx_NEWLINE_xXDiagnosis of metastatic renal cell carcinoma, either clear cell type or non-clear cell type; the diagnosis must be confirmed by the Laboratory of Pathology of National Cancer Institute (NCI) (there will be no central pathology review)Xx_NEWLINE_xXPatients must have histologically confirmed solid tumor malignancy or lymphoma that is metastatic or unresectable and for which effective therapy does not exist or is no longer effectiveXx_NEWLINE_xXPatients must have a histologically confirmed solid tumor that is considered incurable and is not amenable to conventional surgical, radiation therapy or chemotherapy treatment programsXx_NEWLINE_xXHistologically or cytologically confirmed breast carcinomaXx_NEWLINE_xXHistologically or cytologically confirmed HER2-positive invasive breast cancer, with Stage IV disease;Xx_NEWLINE_xXHistologically or cytologically confirmed Stage IIIB, IV (according to AJCC) or recurrent non small cell lung cancer (NSCLC) (non squamous histologies)Xx_NEWLINE_xXThe participant has well-differentiated or moderately-differentiated, histologically confirmed neuroendocrine carcinoma, including carcinoid of any location and islet cell tumorsXx_NEWLINE_xXPatient had histological confirmed diagnosis of osteosarcoma of the recurrent sample.Xx_NEWLINE_xXHistologically or cytologically confirmed salivary gland carcinoma.Xx_NEWLINE_xXHistologically confirmed medulloblastoma located in the posterior fossa            \r\n* Standard-risk diseaseXx_NEWLINE_xXHistologically confirmed SCCHN from any of the following primary sites: oral cavity, oropharynx, hypopharynx, and larynx.Xx_NEWLINE_xXHistologically confirmed stage IV NSCLC (squamous, adenocarcinoma, or large cell carcinoma) that is stable or has partially responded after four cycles of a platinum doublet; (a complete response is not allowed) there is no restriction on prior lines of therapy; maintenance chemotherapy is not allowedXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of metastatic clear-cell renal cell carcinoma (ccRCC)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed stage IV non-small cell lung cancer, or recurrent non-small cell lung cancer which is not amenable to curative intent therapyXx_NEWLINE_xXPatients with a histologically and/or cytologically confirmed solid tumor who are resistant / refractory to approved therapies or for whom no curative therapies are availableXx_NEWLINE_xXHistologically or cytologically confirmed metastatic stage IIIB/IV lung adenocarcinoma with known activating mutations in the EGFR TK domain (including exon 19 deletion and L858R)Xx_NEWLINE_xXSymptomatic, histologically confirmed MM, based on IMWG guidelines. Patients must have measurable disease as defined by at least one of the following:Xx_NEWLINE_xXFor the dose escalation cohort, patients must have histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of mCRCXx_NEWLINE_xXPatients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXPatients with recurrent or metastatic squamous cell carcinoma of the lung – diagnosis must be histologically confirmedXx_NEWLINE_xXHistologically confirmed diagnosis of myelomaXx_NEWLINE_xXPatients must have histologically confirmed diagnosis of recurrent, persistent or advanced (stage IVB) squamous, adenocarcinoma or adenosquamous cervical cancerXx_NEWLINE_xXPatient has a pathologically confirmed diagnosis of clear cell RCCXx_NEWLINE_xXHistologically confirmed diagnosis of metastatic melanoma with the presence of the B-Raf proto-oncogene, serine/threonine kinase (BRAFV600) mutationXx_NEWLINE_xXHistologically confirmed squamous cell carcinoma of the target tumor(s)Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of Stage IIIB or IV NSCLCXx_NEWLINE_xXPatients must have histologically or cytologically confirmed malignant melanoma and clinical evidence of metastatic disease to the brain; mucosal and ocular melanomas are includedXx_NEWLINE_xXHave histologically confirmed organ-confined prostate cancer - Clinical Stage T1 or T2a,Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of solid malignancyXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of prostate cancerXx_NEWLINE_xXHave a confirmed diagnosis of cancerXx_NEWLINE_xXHave histologically or cytologically-confirmed malignant disease in an advanced incurable stageXx_NEWLINE_xXHistologically/cytologically proven primary thoracic or breast malignancy, lymphoma or lung metastases (which are not required to be biopsy-proven) treated with definitive intentXx_NEWLINE_xXPathologically confirmed NHLXx_NEWLINE_xXHistologically confirmed cancer diagnosisXx_NEWLINE_xXWoman histologically diagnosed by an open biopsy procedureXx_NEWLINE_xXHistologically confirmed diagnosis for which an allogeneic transplant is utilizedXx_NEWLINE_xX(Part 1 only) Have a histologically/cytologically confirmed diagnosis of advanced solid tumor, including sarcoma that is refractory to standard therapy. (Part 2 only) Have a histologically confirmed diagnosis of advanced, unresectable, or metastatic soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy.Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of HNSCC associated with HPV by a p16 immunohistochemistry (IHC) assay or HPV-16 or HPV-18 positive by nucleic acid testing.Xx_NEWLINE_xXHistologically confirmed serous carcinoma or endometrioid type of endometrial carcinoma (histological documentation of recurrence is not required);Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed stage IV invasive breast cancer; patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluationXx_NEWLINE_xXHistologically or cytologically confirmed advanced solid tumor with no available standard treatment options in the opinion of the InvestigatorXx_NEWLINE_xXHistologically or cytologically confirmed advanced solid tumor with no available standard approved treatment options in the opinion of the InvestigatorXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction (GEJ); pathology must be confirmed at Memorial Sloan Kettering Cancer CenterXx_NEWLINE_xXHistologically and/or cytologically confirmed diagnosis of ER+/HER2- breast cancerXx_NEWLINE_xXDiagnosis of soft tissue sarcoma that has been histologically confirmed by an approved reference pathologistXx_NEWLINE_xXPatients must have histologically or cytologically confirmed stage II-IV lung cancer and be planned for or within 2 weeks of initiation of initial non-surgical therapyXx_NEWLINE_xXMust have a histologically confirmed cancer diagnosisXx_NEWLINE_xXCytologically or pathologically verified diagnosis of renal cell carcinoma (RCC)Xx_NEWLINE_xXAdolescents and young adults (AYA) with histologically confirmed cancer who have completed primary treatmentXx_NEWLINE_xXHistologically or cytologically confirmed, stage I-III breast cancerXx_NEWLINE_xXRENAL CANCER: Histologically confirmed renal cell carcinoma (RCC)Xx_NEWLINE_xXBRAIN CANCER: Histologically confirmed high grade gliomaXx_NEWLINE_xXHistologically or cytologically-proven non squamous cell NSCLC; mixed histology with small cell lung carcinoma (SCLC) component not allowedXx_NEWLINE_xXHistologically confirmed breast cancer and no evidence of metastatic disease with a recommendation to begin chemotherapy within 4 weeksXx_NEWLINE_xXHistologically confirmed carcinoma of the breastXx_NEWLINE_xXPatients must have histologically confirmed diagnosis of glioma (either low or high grade) and be either chemotherapy naive or non-naive and scheduled to receive temozolomide-based +/- bevacizumab-based chemotherapy; patients with recurrent disease whose diagnostic pathology confirmed glioma (either low or high grade) will not need re-biopsyXx_NEWLINE_xXHistory of histologically confirmed prostate cancerXx_NEWLINE_xXAdult men of all races and body size with histologically confirmed localized PCa on ASXx_NEWLINE_xXPatients must have histologically confirmed high grade astrocytoma, WHO grade III or IV, by pathologyXx_NEWLINE_xXHave histologically confirmed cancerXx_NEWLINE_xXCANCER PATIENT GROUP: Histologically confirmed non-metastatic PCaXx_NEWLINE_xXHistologically or cytologically confirmed cancer (hematologic or solid) who are not currently on hospice careXx_NEWLINE_xXMetastatic, castrate resistant, histologically confirmed prostate cancer; surgically castrated or continuous medical castration for ? 8 weeks prior to screeningXx_NEWLINE_xXPatients with a histologically or cytologically confirmed solid tumor or aggressive NHL who are refractory to or have exhausted all available therapiesXx_NEWLINE_xXFor Part 1: Histologically- or cytologically-confirmed diagnosis of unresectable GIST or another advanced solid tumor. Patients with unresectable GIST must have disease that has progressed following imatinib and at least 1 of the following: sunitinib, regorafenib, sorafenib, dasatinib, pazopanib or an experimental kinase-inhibitor agent, or disease with a D842 mutation in the PDGFR? gene. Patients with an advanced solid tumor other than GIST must have relapsed or refractory disease without an available effective therapy. OR For Part 2:Xx_NEWLINE_xXPatients with stage IV or recurrent/metastatic histologically or cytologically confirmed non-squamous NSCLCXx_NEWLINE_xXAdult patients > 18 years with histologically or cytologically confirmed Peripheral T-cell lymphoma (PTCL)Xx_NEWLINE_xXSubjects with histologically confirmed Stage IV or recurrent NSCLC squamous or non-squamous histology, with no prior systemic anticancer therapyXx_NEWLINE_xXDose escalation: patients must have histologically or cytologically confirmed solid tumor malignancy that is metastatic or unresectable and for whom either standard curative or palliative measures do not exist or are no longer effective, or for whom anti-PD-L1/cytotoxic T-lymphocyte antigen (CTLA)-4 is appropriateXx_NEWLINE_xXHistologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLCXx_NEWLINE_xXMemorial Sloan Kettering (MSK) histologically confirmed metastatic breast cancerXx_NEWLINE_xXPatients must have histologically or cytologically confirmed colorectal or pancreatic carcinomaXx_NEWLINE_xXPatient must have histologically or cytologically confirmed small cell lung cancer; patients with either limited or extensive stage disease are eligibleXx_NEWLINE_xXPatients with histologically confirmed diagnosis of cancer; NOTE: patients with active cancer or post treatment are allowed on the studyXx_NEWLINE_xXPatients with suspected but no biopsy confirmed BEXx_NEWLINE_xXHistologically-confirmed high grade dysplasia (HGD), cancer, or polyp burden that is not quantifiableXx_NEWLINE_xXNaïve or non-naïve patient with histologically, and/or cytologically (or imaging in the case of brain tumors) confirmed malignant disease.Xx_NEWLINE_xXHistologically-confirmed chronic multifocal atrophic gastritis (MAG) and/or gastric intestinal metaplasia (GIM)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed squamous cell carcinoma of the nasopharynx, oropharynx, larynx, hypopharynx, oral cavityXx_NEWLINE_xXHistologically confirmed BE with high grade dysplasia, invasive carcinoma of the esophagus, low grade dysplasiaXx_NEWLINE_xXMen and women, 18 years or older, with histologically or cytologically-confirmed either:Xx_NEWLINE_xXHistologically confirmed supratentorial glioblastoma or other WHO grade III or IV malignant glioma from archival tissue.Xx_NEWLINE_xXParticipant must have histologically confirmed Ewing’s sarcomaXx_NEWLINE_xXParticipants must have histologically confirmed diagnosis of a solid tumor for which no curative therapy existsXx_NEWLINE_xXA histologically or cytologically confirmed ovarian, breast, non-small cell lung, melanoma, gastric/GEJ/esophageal or other type of advanced cancer that is metastatic, unresectable, or recurrent and for which weekly paclitaxel is an acceptable therapeutic option.Xx_NEWLINE_xXHistologically or cytologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN)Xx_NEWLINE_xXHistologically proven diagnosis of GBM.Xx_NEWLINE_xXHistologically proven squamous cell carcinoma of the head and neck (SCCHN) from one of the following primary sites: oral cavity, oropharynx, hypopharynx, and larynxXx_NEWLINE_xXHistologically or cytologically confirmed breast cancerXx_NEWLINE_xXSubject must have histologically confirmed at last relapse aggressive B-cell NHL according to \The 2016 revision of the WHO classification of lymphoid neoplasms\ defined as:Xx_NEWLINE_xXRecently-diagnosed (within the last 6 months), histologically-documented, non-metastatic squamous cell carcinoma of the oral cavity and/or oropharynx amenable to radiotherapy with concurrent chemotherapy as the definitive treatment modality.Xx_NEWLINE_xXPatients who are scheduled to receive a taxane-based regimen for a histologically confirmed solid tumor that is:Xx_NEWLINE_xXHistologically confirmed metastatic breast cancerXx_NEWLINE_xXParticipants must have evidence of metastatic cancer to the brain for cohort A or histologically confirmed glioblastoma (GBM) for cohorts B and CXx_NEWLINE_xXHistologically confirmed prostate cancerXx_NEWLINE_xXParticipants must have histologically confirmed glioblastoma and evidence of recurrence; patients with low-grade tumors who have progressed to glioblastoma are eligibleXx_NEWLINE_xXHistologically confirmed diagnosis of malignant primary brain tumor or known metastatic cancer with brain lesion presumed to be metastaticXx_NEWLINE_xXHistologically confirmed renal cell carcinomaXx_NEWLINE_xXPathologically (histologically or cytologically) proven diagnosis of cervical, vulvar, esophageal and anal canal cancerXx_NEWLINE_xXHave a histologically-confirmed diagnosis of breast cancerXx_NEWLINE_xXPatients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary and its respective variants)Xx_NEWLINE_xXHistologically or cytologically proven squamous cell carcinoma of the oral cavity or pharynx (OSCC)Xx_NEWLINE_xXHistologically confirmed cT0-4, N1 breast cancerXx_NEWLINE_xXHistologically or cytologically documented cancer to which anti-PD1 or anti-PDL1 are approved therapiesXx_NEWLINE_xXPatients with histologically proven high grade gliomaXx_NEWLINE_xXPatients must have histologically or cytologically confirmed diagnosis of unresectable, stage III or metastatic melanomaXx_NEWLINE_xXHistologically-confirmed high-grade gliomaXx_NEWLINE_xXParticipants must have histologically confirmed glioblastoma and evidence of possible tumor progression on imaging; patients with low-grade tumors who have progressed to glioblastoma are eligibleXx_NEWLINE_xXPatients must have histologically or cytologically proven advanced non-squamous NSCLC; patients may have newly diagnosed recurrent progressive or refractory disease which may be localized or wide spreadXx_NEWLINE_xXPatients with histologically confirmed malignancy (local or metastatic, newly diagnosed or recurrent disease)Xx_NEWLINE_xXHistory of histologically confirmed melanoma as assessed per medical record reviewXx_NEWLINE_xXHistologically confirmed cancer that is advanced; metastatic; or otherwise not suitable for surgical resection with curative intentXx_NEWLINE_xXPatients must have histologically or cytologically confirmed prostate cancer confirmed by the Laboratory of Pathology, National Cancer Institute (NCI) or Pathology Department at Walter Reed BethesdaXx_NEWLINE_xXPatients with history of histologically-confirmed malignant solid tumor (histology confirmed by Memorial Sloan-Kettering Cancer Center [MSKCC] Department of Pathology); NOTE: an exception will be made for patients with brain lesions; patients identified by a radiologist to have a brain lesion with high suspicion for neoplasm given MRI features will be enrolled, prior to histological confirmationXx_NEWLINE_xXPatients must have histologically confirmed primary or metastatic cancer; if biopsies were performed at an outside facility, the histology must be reviewed and confirmed by the Department of Pathology at the City of HopeXx_NEWLINE_xXHistologically confirmed newly diagnosed grade IV malignant glioma; Note: grade III patients are no longer being enrolledXx_NEWLINE_xXPatients must have histologically or cytologically confirmed prostate cancer; the outside pathology report is acceptable for study entry; every effort will be made to acquire the outside pathology slides to be confirmed by the Laboratory of Pathology, National Cancer Institute (NCI)Xx_NEWLINE_xXPatients must have a history of histologically or cytologically confirmed prostate cancer; the outside pathology report is acceptable for study entry; every effort will be made to acquire the outside pathology slides to be confirmed by the Laboratory of Pathology, NCIXx_NEWLINE_xXPatients with history of histologically-confirmed solid malignancy and/or lymphoma (histology confirmed by Memorial Sloan-Kettering Cancer Center (MSKCC) Department of Pathology)Xx_NEWLINE_xXHistologically-confirmed prostate cancerXx_NEWLINE_xXHistologically confirmed diagnosis of melanoma or malignant brain tumor at Memorial Sloan-Kettering Cancer Center (MSKCC)Xx_NEWLINE_xXSubjects with radiographically suspected, histologically or cytologically confirmed primary brain tumors or brain metastasis are eligibleXx_NEWLINE_xXPatients with histologically confirmed prostate cancerXx_NEWLINE_xXPathologically (histologically or cytologically) proven diagnosis of carcinomaXx_NEWLINE_xXHave histologically or cytologically confirmed small bowel carcinoid tumorXx_NEWLINE_xXPatients with histologically-confirmed (confirmation done at Memorial Sloan-Kettering Cancer Center [MSKCC]) malignanciesXx_NEWLINE_xXWomen with histologically confirmed breast cancer (by core needle biopsy)Xx_NEWLINE_xXParticipants must have histologically confirmed prostate cancerXx_NEWLINE_xXHistologically confirmed diagnosis of prostate cancerXx_NEWLINE_xXHistologically or cytologically confirmed head and neck squamous cell carcinoma.Xx_NEWLINE_xXDose and Disease Expansion Cohorts: histologically confirmed renal cell carcinoma, gastric carcinoma (including gastro-esophageal junction adenocarcinoma), and a biomarker driven cohort of tumors with evidence of c-MET dysregulation (amplification, mutation)Xx_NEWLINE_xXHistologically confirmed HCC, not amenable to transplant, resection or loco-regional therapyXx_NEWLINE_xXHistologically confirmed MM with measurable disease per IMWG guidelines as defined by at least 1 of the following:Xx_NEWLINE_xXHistopathologically confirmed diagnosis of metastatic or unresectable malignant melanoma arising from skin. Ocular melanoma subjects are not eligible.Xx_NEWLINE_xXParticipants must have histologically confirmed intracranial meningioma, grade II-III, that has recurred or progressed after previous treatmentXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of NSCLC that is EGFR Wild-type, ALK-negative rearrangement and ROS1-negative rearrangementXx_NEWLINE_xXHistologically confirmed, measurable, unresectable adenocarcinoma or squamous cell carcinoma of the esophagus; for the purposes of this study, undifferentiated carcinomas or adenosquamous carcinomas will be categorized as adenocarcinomasXx_NEWLINE_xXFor Parts A and B: Has histologically or cytologically confirmed metastatic solid tumorXx_NEWLINE_xXFor patients enrolling once escalation is complete, disease must be measurable per RECIST 1.1 criteria with last imaging performed within 28 days prior to first drug dose In addition to the criterion listed above, Patients in Phase 2a must have a histologically- or cytologically-confirmed, advanced or metastatic solid tumor, in 1 of the following categories: disease history specificied in one of the criteria listed below:Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC) (stage IV, American Joint Committee on Cancer [AJCC] v7.0) that carries (a) an ALK rearrangement, as determined by fluorescence in-situ hybridization (FISH), immunohistochemistry, or next generation sequencing (NGS) of either tissue or plasma, or (b) a ROS1 rearrangement as determined by FISH or reverse transcriptase-polymerase chain reaction (RT-PCR) or NGS via a local diagnostic test (LDT) or plasma analysisXx_NEWLINE_xXPatients must either have histologic or pathologically confirmed non-small cell lung cancer (NSCLC) or suspicious nodules/lesions which are going to be surgically resected before they are pathologically confirmedXx_NEWLINE_xXHistologically confirmed clear cell carcinoma (conventional) with advanced and/or metastatic diseaseXx_NEWLINE_xXHistologically confirmed diagnosis of head and neck carcinoma (excluding nasopharynx, paranasal sinus, salivary, and thyroid malignancies); any unknown primary squamous cell carcinoma of head and neck with gross nodes is allowedXx_NEWLINE_xXPatients who have histologically proven transitional cell carcinoma (TCC); orXx_NEWLINE_xXa primary brain tumor that has been histologically confirmedXx_NEWLINE_xXOR confirmed or suspected recurrent brain cancer or brain metastasis for which the primary tumor has been histologically confirmed,Xx_NEWLINE_xXPatients must have either \r\n* 1) histologically/cytologically-confirmed borderline resectable pancreatic cancer and be prescribed neoadjuvant gemcitabine-plus-Abraxane as part of their standard of care, or \r\n* 2) histologically/cytologically-confirmed locally advanced unresectable pancreatic cancer and be prescribed neoadjuvant gemcitabine-plus-Abraxane as part of their standard of careXx_NEWLINE_xXWomen must have newly diagnosed histologically or cytologically confirmed endometrial cancerXx_NEWLINE_xXMediastinal nodal metastases (N2) disease must be confirmed histologicallyXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed hepatocellular carcinoma OR have an imaging study that demonstrates a focal hepatic lesion with imaging features diagnostic of hepatocellular carcinomaXx_NEWLINE_xXPatients with histologically confirmed prostate cancerXx_NEWLINE_xXPatients must have histologically confirmed glioblastoma/gliosarcoma confirmed by the Laboratory of Pathology, National Cancer Institute (NCI)Xx_NEWLINE_xXHistologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXPatients must have histologically-confirmed HNSCC with surgically resectable diseaseXx_NEWLINE_xXHistologically or cytologically confirmed solid malignancy or lymphoma that is metastatic or unresectable, and for which standard curative or palliative measures do not exist, or are no longer effective. In case of hepatocellular carcinoma, the diagnosis should be based on at least one of the following:Xx_NEWLINE_xXPatients must have histologically confirmed head-and-neck, lung, or prostate tumorsXx_NEWLINE_xXPatients must have histologically or cytologically confirmed prostate cancer confirmed by the Laboratory of Pathology, National Cancer Institute (NCI) or Pathology Department of the Walter Reed National Military Medical CenterXx_NEWLINE_xXHistologically or cytologically confirmed measurable advanced and/or metastatic solid GI tumor that expresses GCC protein (H-score greater than [>] 10), for which standard treatment is no longer effective or does not offer curative or life-prolonging benefit. For the escalation part of the study (Part A), GI malignancies include, but are not limited to, metastatic colorectal carcinoma (mCRC), gastric carcinoma, esophageal carcinoma, small intestine cancer, and pancreatic cancer. The expansion part of the study (Part B) is limited to participants with CRC.Xx_NEWLINE_xXHistologically or cytologically confirmed primary breast cancer.Xx_NEWLINE_xXMust have a histologically or cytologically confirmed metastatic and/or advanced solid tumor and/or lymphoma for which standard curative or life-prolonging treatment does not exist, or is no longer effective or tolerable.Xx_NEWLINE_xXHistologically confirmed:Xx_NEWLINE_xXHistologically confirmed newly diagnosed G4 MGXx_NEWLINE_xXHistologically or cytologically-confirmed advanced or metastatic GIST with a D842V mutation in the PDGFRA gene as determined by central laboratory testingXx_NEWLINE_xXHistologically confirmed recurrent or metastatic squamous cell carcinoma of unknown primary or nonsquamous histologies (example, mucosal melanoma) are not allowed.Xx_NEWLINE_xXAge ? 18 years with histologically- or cytologically-confirmed, extensive-stage, chemotherapy-naïve SCLCXx_NEWLINE_xXHistologically or cytologically confirmed metastatic NSCLC including recurrent diseaseXx_NEWLINE_xXPatients with a histologically confirmed solid tumor:Xx_NEWLINE_xXHistologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed diagnosis of one of the following differentiated thyroid cancer (DTC) subtypes:Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of Ewing sarcoma (including ESFT) in subjects with relapsed or refractory disease who have failed standard therapyXx_NEWLINE_xXHistologically or cytologically-confirmed, HPV (+) or HPV (-) squamous cell carcinoma of the nasopharynx (WHO Type 1), oropharynx, hypopharynx, larynx (supraglottis, glottis, subglottis) or oral cavity,Xx_NEWLINE_xX